Updated on 2023/06/05

写真a

 
Nakajo Masatoyo
 
Organization
Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area Graduate School of Medical and Dental Sciences Advanced Therapeutics Course Oncology Lecturer
Title
Lecturer

Degree

  • 博士 (医学) ( 2008.10   鹿児島大学 )

Research Areas

  • Others / Others  / 核医学

  • Others / Others  / 放射線診断学

Education

  • Kagoshima University

    2002.4 - 2008.10

      More details

    Country: Japan

  • Yamaguchi University

    1994.4 - 2000.3

      More details

    Country: Japan

Research History

  • Kagoshima University   Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area Graduate School of Medical and Dental Sciences Advanced Therapeutics Course Oncology   Lecturer

    2022.12

  • Kagoshima University   Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area Graduate School of Medical and Dental Sciences Advanced Therapeutics Course Oncology   Assistant Professor

    2018.4 - 2022.11

  • Kagoshima University   Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area Graduate School of Medical and Dental Sciences Advanced Therapeutics Course   Assistant Professor

    2003.4 - 2017.3

Professional Memberships

  • 日本核医学会

    2015.10

  • 日本医学放射線学会

    2015.10

 

Papers

  • Takumi K, Nagano H, Oose A, Gohara M, Kamimura K, Nakajo M, Harada-Takeda A, Ueda K, Tabata K, Yoshiura T .  Extracellular volume fraction derived from equilibrium contrast-enhanced CT as a diagnostic parameter in anterior mediastinal tumors. .  European journal of radiology165   110891   2023.5Extracellular volume fraction derived from equilibrium contrast-enhanced CT as a diagnostic parameter in anterior mediastinal tumors.

     More details

    Language:English  

    DOI: 10.1016/j.ejrad.2023.110891

    PubMed

  • 西山 佳宏, 沖崎 貴琢, 乾 好貴, 大塚 秀樹, 高浪 健太郎, 中條 正豊, 中谷 航也, 野上 宗伸, 平田 健司, 前田 幸人, 吉村 真奈, 若林 大志, (公社)日本アイソトープ協会医学・薬学部会全国核医学診療実態調査専門委員会 .  (第9回)全国核医学診療実態調査報告書 .  Radioisotopes72 ( 1 ) 49 - 100   2023.3(第9回)全国核医学診療実態調査報告書

     More details

    Language:Japanese   Publisher:(公社)日本アイソトープ協会  

  • Kawaji K., Nakajo M., Shinden Y., Jinguji M., Tani A., Hirahara D., Kitazono I., Ohtsuka T., Yoshiura T. .  Application of Machine Learning Analyses Using Clinical and [<sup>18</sup>F]-FDG-PET/CT Radiomic Characteristics to Predict Recurrence in Patients with Breast Cancer .  Molecular Imaging and Biology   2023

     More details

    Language:Japanese   Publisher:Molecular Imaging and Biology  

    Purpose: To develop and identify machine learning (ML) models using pretreatment clinical and 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography ([18F]-FDG-PET)-based radiomic characteristics to predict disease recurrences in patients with breast cancers who underwent surgery. Procedures: This retrospective study included 112 patients with 118 breast cancer lesions who underwent [18F]-FDG-PET/ X-ray computed tomography (CT) preoperatively, and these lesions were assigned to training (n=95) and testing (n=23) cohorts. A total of 12 clinical and 40 [18F]-FDG-PET-based radiomic characteristics were used to predict recurrences using 7 different ML algorithms, namely, decision tree, random forest (RF), neural network, k-nearest neighbors, naive Bayes, logistic regression, and support vector machine (SVM) with a 10-fold cross-validation and synthetic minority over-sampling technique. Three different ML models were created using clinical characteristics (clinical ML models), radiomic characteristics (radiomic ML models), and both clinical and radiomic characteristics (combined ML models). Each ML model was constructed using the top ten characteristics ranked by the decrease in Gini impurity. The areas under ROC curves (AUCs) and accuracies were used to compare predictive performances. Results: In training cohorts, all 7 ML algorithms except for logistic regression algorithm in the radiomics ML model (AUC = 0.760) achieved AUC values of >0.80 for predicting recurrences with clinical (range, 0.892–0.999), radiomic (range, 0.809–0.984), and combined (range, 0.897–0.999) ML models. In testing cohorts, the RF algorithm of combined ML model achieved the highest AUC and accuracy (95.7% (22/23)) with similar classification performance between training and testing cohorts (AUC: training cohort, 0.999; testing cohort, 0.992). The important characteristics for modeling process of this RF algorithm were radiomic GLZLM_ZLNU and AJCC stage. Conclusions: ML analyses using both clinical and [18F]-FDG-PET-based radiomic characteristics may be useful for predicting recurrence in patients with breast cancers who underwent surgery.

    DOI: 10.1007/s11307-023-01823-8

    Scopus

    PubMed

  • Nakamoto Y., Kitajima K., Toriihara A., Nakajo M., Hirata K. .  Recent topics of the clinical utility of PET/MRI in oncology and neuroscience .  Annals of Nuclear Medicine36 ( 9 ) 798 - 803   2022.9

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Since the inline positron emission tomography (PET)/magnetic resonance imaging (MRI) system appeared in clinical, more than a decade has passed. In this article, we have reviewed recently-published articles about PET/MRI. There have been articles about staging in rectal and breast cancers by PET/MRI using fluorodeoxyglucose (FDG) with higher diagnostic performance in oncology. Assessing possible metastatic bone lesions is considered a proper target by FDG PET/MRI. Other than FDG, PET/MRI with prostate specific membrane antigen (PSMA)-targeted tracers or fibroblast activation protein inhibitor have been reported. Especially, PSMA PET/MRI has been reported to be a promising tool for determining appropriate sites in biopsy. Independent of tracers, the clinical application of artificial intelligence (AI) for images obtained by PET/MRI is one of the current topics in this field, suggesting clinical usefulness for differentiating breast lesions or grading prostate cancer. In addition, AI has been reported to be helpful for noise reduction for reconstructing images, which would be promising for reducing radiation exposure. Furthermore, PET/MRI has a clinical role in neuroscience, including localization of the epileptogenic zone. PET/MRI with new PET tracers could be useful for differentiation among neurological disorders. Clinical applications of integrated PET/MRI in various fields are expected to be reported in the future.

    DOI: 10.1007/s12149-022-01780-2

    Scopus

    PubMed

  • Yano E., Nakajo M., Jinguji M., Tani A., Kitazono I., Yoshiura T. .  I-131 false-positive uptake in a thymic cyst with expression of the sodium-iodide symporter: A case report .  Medicine (United States)101 ( 26 ) e29282   2022.6

     More details

    Language:English   Publisher:Medicine (United States)  

    Rationale: I-131 radioiodine false-positive findings in postoperative patients with differentiated thyroid cancer (DTC) should be recognized to avoid unnecessary therapies. Patient concerns and diagnoses: A 50-year-old man underwent I-131 therapy 3 times, including the initial ablative therapy after total thyroidectomy for papillary thyroid cancer. The initial I-131 posttherapeutic whole-body scintigraphy showed 2 cervical and one superior mediastinal focal I-131 positive uptake lesions. The serum thyroglobulin level was negative every time when the radioiodine therapy was performed. Although the 2 cervical positive uptake lesions disappeared after the second therapy, the superior mediastinal I-131 positive uptake persisted even after the third therapy, and this lesion was suspicion of I-131 therapy-resistant node metastasis. Interventions and outcomes: The lesion was resected, and the pathological diagnosis with immune-histochemical analysis was a thymic cyst with thymic epithelial cells having a weak expression of the sodium-iodide symporter (NIS). Lessons: The false-positive result may be attributed to the NIS expression in the thymic cyst epithelial cells. It is necessary to include a thymic cyst in the differential diagnosis, when I-131 uptake is noted in the superior mediastinal region on I-131 posttherapeutic scans of patients with postoperative DTC. Although the I-131 positive uptake in a thymic cyst may be influenced by the I-131 administered dose and scan timing after I-131 administration, the NIS expression may be essential to the false-positive uptake in a thymic cyst.

    DOI: 10.1097/MD.0000000000029282

    Scopus

    PubMed

  • Nakajo M., Takeda A., Katsuki A., Jinguji M., Ohmura K., Tani A., Sato M., Yoshiura T. .  The efficacy of<sup>18</sup>F-FDG-PET-based radiomic and deep-learning features using a machine-learning approach to predict the pathological risk subtypes of thymic epithelial tumors .  British Journal of Radiology95 ( 1134 ) 20211050   2022.6

     More details

    Language:English   Publisher:British Journal of Radiology  

    Objective: To examine whether the machine-learning approach using 18-fludeoxyglucose positron emission tomography (18F-FDG-PET)-based radiomic and deep-learning features is useful for predicting the pathological risk subtypes of thymic epithelial tumors (TETs). Methods: This retrospective study included 79 TET [27 low-risk thymomas (types A, AB and B1), 31 high-risk thymomas (types B2 and B3) and 21 thymic carcinomas] patients who underwent pre-therapeutic18F-FDG-PET/ CT. High-risk TETs (high-risk thymomas and thymic carcinomas) were 52 patients. The 107 PET-based radiomic features, including SUV-related parameters [maximum SUV (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG)] and 1024 deep-learning features extracted from the convolutional neural network were used to predict the pathological risk subtypes of TETs using six different machine-learning algorithms. The area under the curves (AUCs) were calculated to compare the predictive performances. Results: SUV-related parameters yielded the following AUCs for predicting thymic carcinomas: SUVmax 0.713, MTV 0.442, and TLG 0.479 or high-risk TETs: SUVmax 0.673, MTV 0.533, and TLG 0.539. The bestperforming algorithm was the logistic regression model for predicting thymic carcinomas (AUC 0.900, accuracy 81.0%), and the random forest (RF) model for high-risk TETs (AUC 0.744, accuracy 72.2%). The AUC was significantly higher in the logistic regression model than three SUV-related parameters for predicting thymic carcinomas, and in the RF model than MTV and TLG for predicting high-risk TETs (each; p < 0.05). Conclusion:18F-FDG-PET-based radiomic analysis using a machine-learning approach may be useful for predicting the pathological risk subtypes of TETs. Advances in knowledge: Machine-learning approach using18F-FDG-PET-based radiomic features has the potential to predict the pathological risk subtypes of TETs.

    DOI: 10.1259/bjr.20211050

    Scopus

    PubMed

  • Kitajima Kazuhiro, Watabe Tadashi, Nakajo Masatoyo, Ishibashi Mana, Daisaki Hiromitsu, Soeda Fumihiko, Tanemura Atsushi, Kanekura Takuro, Yamazaki Naoya, Ito Kimiteru .  18F-FDG PET/CT検査による免疫チェックポイント阻害剤療法を受けた悪性黒色腫患者の腫瘍縮小効果判定と予後予測 EORTC法、PERCIST法、imPERCIST法との比較による多施設共同研究(Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter sutdy for comparison of EORTC, PERCIST, and imPERCIST) .  Japanese Journal of Radiology40 ( 1 ) 75 - 85   2022.118F-FDG PET/CT検査による免疫チェックポイント阻害剤療法を受けた悪性黒色腫患者の腫瘍縮小効果判定と予後予測 EORTC法、PERCIST法、imPERCIST法との比較による多施設共同研究(Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter sutdy for comparison of EORTC, PERCIST, and imPERCIST)

     More details

    Language:English   Publisher:(公社)日本医学放射線学会  

    免疫チェックポイント阻害剤(ICI)療法が施行された悪性黒色腫患者に対し、3種類の18F-FDG PET/CTによる治療効果判定法(EORTC法、PERCIST法、imPERCIST法)を用いて、腫瘍縮小効果判定能と予後予測能を比較した。調査対象者は2014年8月~2019年10月までの期間内に、後向き多施設共同研究に参加した国内医療施設5施設で、PD-1阻害剤もしくはPD-L1阻害剤療法が施行された悪性黒色腫患者27例(男性18例、女性9例、年齢39~86歳)とした。FDG PET/CT検査は治療前、治療(ニボルマブ投与は21例、ペムブロリズマブ投与は6例)開始後3~9ヵ月行い、治療効果判定はEORTC法、PERCIST法、imPERCIST法で評価した。その結果、harmonized EORTC、PERCIST、imPERCISTによる完全代謝奏効(CMR)/部分代謝奏効(PMR)/安定代謝(SMD)/進行代謝(PMD)は、それぞれ3例/5例/4例/15例、4例/5例/3例/15例、4例/5例/5例/13例で、各治療効果判定法で概ね完全な一致が得られた。しかし、うち20例では悪性黒色腫が進行し、14例は中央値19.2ヵ月後に死亡が確認され、治療奏効患者(CMR/PMR)では非治療奏効患者(SMD/PMD)に比べ、有意にPFSとOSが長かった。以上より、今回評価した3種のharmonized FDG-PET治療効果判定法(EORTC法、PERCIST法、imPERCIST法)により、CMR/PMR/SMD/PMDで高い一致度が得られ、ICI療法の治療効果(腫瘍縮小効果)判定、悪性黒色腫患者の予後予測能が高精度であることが確認された。

  • 北島 一宏, 中原 理紀, 中條 正豊, 渡部 直史, 石橋 愛, 伊藤 公輝, 鳥井原 彰, 坂本 史, 大﨑 洋充 .  平成31年・令和2年度 ワーキンググループ報告 .  核医学59 ( 1 ) 23 - 24   2022平成31年・令和2年度 ワーキンググループ報告

     More details

    Language:Japanese   Publisher:一般社団法人 日本核医学会  

    DOI: 10.18893/kakuigaku.wgr.2234

  • Nakajo M., Kawaji K., Nagano H., Jinguji M., Mukai A., Kawabata H., Tani A., Hirahara D., Yamashita M., Yoshiura T. .  The Usefulness of Machine Learning–Based Evaluation of Clinical and Pretreatment [<sup>18</sup>F]-FDG-PET/CT Radiomic Features for Predicting Prognosis in Hypopharyngeal Cancer .  Molecular Imaging and Biology25 ( 2 ) 303 - 313   2022

     More details

    Language:English   Publisher:Molecular Imaging and Biology  

    Purpose: To examine whether the machine learning (ML) analyses using clinical and pretreatment 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography ([18F]-FDG-PET)–based radiomic features were useful for predicting prognosis in patients with hypopharyngeal cancer. Procedures: This retrospective study included 100 patients with hypopharyngeal cancer who underwent [18F]-FDG-PET/X-ray computed tomography (CT) before treatment, and these patients were allocated to the training (n=80) and validation (n=20) cohorts. Eight clinical (age, sex, histology, T stage, N stage, M stage, UICC stage, and treatment) and 40 [18F]-FDG-PET–based radiomic features were used to predict disease progression. A feature reduction procedure based on the decrease of the Gini impurity was applied. Six ML algorithms (random forest, neural network, k-nearest neighbors, naïve Bayes, logistic regression, and support vector machine) were compared using the area under the receiver operating characteristic curve (AUC). Progression-free survival (PFS) was assessed using Cox regression analysis. Results: The five most important features for predicting disease progression were UICC stage, N stage, gray level co-occurrence matrix entropy (GLCM_Entropy), gray level run length matrix run length non-uniformity (GLRLM_RLNU), and T stage. Patients who experienced disease progression displayed significantly higher UICC stage, N stage, GLCM_Entropy, GLRLM_RLNU, and T stage than those without progression (each, p<0.001). In both cohorts, the logistic regression model constructed by these 5 features was the best performing classifier (training: AUC=0.860, accuracy=0.800; validation: AUC=0.803, accuracy=0.700). In the logistic regression model, 5-year PFS was significantly higher in patients with predicted non-progression than those with predicted progression (75.8% vs. 8.3%, p<0.001), and this model was only the independent factor for PFS in multivariate analysis (hazard ratio = 3.22; 95% confidence interval = 1.03–10.11; p=0.045). Conclusions: The logistic regression model constructed by UICC, T and N stages and pretreatment [18F]-FDG-PET–based radiomic features, GLCM_Entropy, and GLRLM_RLNU may be the most important predictor of prognosis in patients with hypopharyngeal cancer.

    DOI: 10.1007/s11307-022-01757-7

    Scopus

    PubMed

  • Tanaka T., Nakajo M., Kawakami H., Motomura E., Fujisaka T., Ojima S., Saigo Y., Yoshiura T. .  Short-time-window Patlak imaging using a population-based arterial input function and optimized Bayesian penalized likelihood reconstruction: a feasibility study .  EJNMMI Research12 ( 1 ) 57   2022

     More details

    Language:English   Publisher:EJNMMI Research  

    Background: To explore the feasibility of short-time-window Ki imaging using a population-based arterial input function (IF) and optimized Bayesian penalized likelihood (BPL) reconstruction as a practical alternative to long-time-window Ki imaging with an individual patient-based IF. Myocardial Ki images were generated from 73 dynamic 18F-FDG-PET/CT scans of 30 patients with cardiac sarcoidosis. For each dynamic scan, the Ki images were obtained using the IF from each individual patient and a long time window (10–60 min). In addition, Ki images were obtained using the normalized averaged population-based IF and BPL algorithms with different beta values (350, 700, and 1000) with a short time window (40–60 min). The visual quality of each image was visually rated using a 4-point scale (0, not visible; 1, poor; 2, moderate; and 3, good), and the Ki parameters (Ki-max, Ki-mean, Ki-volume) of positive myocardial lesions were measured independently by two readers. Wilcoxon’s rank sum test, McNemar’s test, or linear regression analysis were performed to assess the differences or relationships between two quantitative variables. Results: Both readers similarly rated 51 scans as positive (scores = 1–3) and 22 scans as negative (score = 0) for all four Ki images. Among the three types of population-based IF Ki images, the proportion of images with scores of 3 was highest with a beta of 1000 (78.4 and 72.5%, respectively) and lowest with a beta of 350 (33.3 and 23.5%) for both readers (all p < 0.001). The coefficients of determination between the Ki parameters obtained with the individual patient-based IF and those obtained with the population-based IF were highest with a beta of 1000 for both readers (Ki-max, 0.91 and 0.92, respectively; Ki-mean, 0.91 and 0.92, respectively; Ki-volume, 0.75 and 0.60, respectively; and all p < 0.001). Conclusions: Short-time-window Ki images with a population-based IF reconstructed using the BPL algorithm and a high beta value were closely correlated with long-time-window Ki images generated with an individual patient-based IF. Short-time-window Ki images using a population-based IF and BPL reconstruction might represent practical alternatives to long-time-window Ki images generated using an individual patient-based IF.

    DOI: 10.1186/s13550-022-00933-8

    Scopus

    PubMed

  • Nakajo M., Horizoe Y., Kawaji K., Jinguji M., Tani A., Fukukura Y., Ohishi M., Yoshiura T. .  Application of <sup>123</sup>I-MIBG myocardial maximum standardized uptake value to characterize cardiac function in patients with pheochromocytoma: comparison with echocardiography .  Japanese Journal of Radiology41 ( 4 ) 437 - 448   2022

     More details

    Language:English   Publisher:Japanese Journal of Radiology  

    Purpose: This study examined the usefulness of the maximum standardized uptake value (SUVmax) of myocardial [123I]-metaiodobenzylguanidine ([123I]-MIBG) to characterize myocardial function by comparing it with echocardiographic parameters in patients with pheochromocytoma. Materials and methods: This study included 18 patients with pheochromocytoma who underwent both planar and [123I]-MIBG single-photon emission computed tomography/computed tomography scans and echocardiography before surgery. Myocardial [123I]-MIBG visibility and SUVmax were compared with echocardiographic parameters related to systolic and diastolic functions. The Mann–Whitney U test, Fisher exact test, or Spearman rank correlation assessed differences or relationships between two quantitative variables. Results: On visual analysis, 6 patients showed normal myocardial [123I]-MIBG uptake, whereas 12 patients showed decreased myocardial [123I]-MIBG uptake. No patients showed systolic dysfunction. A significant difference was observed in the incidence of diastolic dysfunction between the groups with normal and decreased uptake (p = 0.009), and left ventricular (LV) diastolic dysfunction was observed in 9 (75%) of 12 patients with decreased myocardial uptake. The myocardial SUVmax was significantly lower in 9 patients with LV diastolic dysfunction than in 9 patients with normal cardiac function (1.67 ± 0.37 vs. 3.03 ± 1.38, p = 0.047). Myocardial SUVmax was positively correlated with septal e′ (early diastolic velocity of septal mitral annulus) (ρ = 0.51, p = 0.031) and negatively correlated with the septal E/e′ ratio (early mitral E-velocity to early diastolic velocity of septal mitral annulus; ρ = − 0.64, p = 0.004), respectively. Conclusions: LV diastolic dysfunction was inversely related to myocardial [123I]-MIBG uptake. Myocardial [123I]-MIBG SUVmax may be useful for characterizing cardiac function in patients with pheochromocytoma. Second abstract. The semiquantitative analysis using the myocardial SUVmax in 123I-MIBG SPECT/CT was found to be potentially useful for characterizing cardiac function in patients with pheochromocytoma.

    DOI: 10.1007/s11604-022-01365-z

    Scopus

    PubMed

  • Daisaki H. .  Usefulness of semi-automatic harmonization strategy of standardized uptake values for multicenter PET studies .  Scientific Reports11 ( 1 ) 8517   2021.12

     More details

    Language:English   Publisher:Scientific Reports  

    This study assessed the possibility of semi-automatic harmonization of standardized uptake values (SUVs) in multicenter studies. Phantom data were acquired using 16 PET/CT scanners (including 3 PET/CT scanners with a silicon photomultiplier detector). PET images obtained using 30-min/bed scans for optimum harmonization filter calculations and using 90–180-s/bed scans for SUV validation under clinical conditions were obtained. Time of flight and a reconstruction method with point-spread function correction were allowed. The optimal full width at half maximum of the 3D-Gaussian filter that minimizes the root mean square error with the median value of the JSNM harmonization range was calculated semi-automatically. The SUVmax and the SUVpeak of the hot spheres were measured, and the inter-scanner coefficient of variation (COV) was calculated before and after harmonization. The harmonization filter was applied to 11 of the 15 PET/CT scanners in which the SUV calibration accuracy had been verified, but not in the remaining 4 scanners. Under noiseless conditions before harmonization, the inter-scanner COVs of the SUVmax and the SUVpeak were as high as 21.57% and 12.20%, respectively, decreasing to 8.79% and 5.73% after harmonization, respectively. Harmonization brought the SUVmax of all the hot spheres to within the harmonization range. Even under clinical conditions affected by image noise, the inter-scanner COVs for the SUVmax and SUVpeak were as high as 8.83% and 5.18% after harmonization, respectively. By applying an optimal harmonization filter that is calculated semi-automatically, the harmonization of SUVs according to the JSNM strategy is possible in multicenter studies, thereby reducing inter-scanner COVs.

    DOI: 10.1038/s41598-021-87942-0

    Scopus

    PubMed

  • Nakajo M. .  Value of Patlak Ki images from <sup>18</sup>F-FDG-PET/CT for evaluation of the relationships between disease activity and clinical events in cardiac sarcoidosis .  Scientific Reports11 ( 1 ) 2729   2021.12

     More details

    Language:English   Publisher:Scientific Reports  

    The association between 18F-fluorodeoxyglucose (18F-FDG) myocardial uptake and clinical presentations in cardiac sarcoidosis (CS) has not yet been clarified. The Patlak slope, Ki, which represents the rate of 18F-FDG uptake is a quantitative index of 18F-FDG metabolism. This study aims to investigate the usefulness of standardized uptake value (SUV) and Patlak Ki images (Ki images) extracted from dynamic 18F-FDG-PET/CT for evaluating the risk of clinical events (CEs) in CS. The SUV and Ki myocardial images were generated from 30 dynamic 18F-FDG-PET/CT scans of 21 CS patients. The SUV and Ki images both were rated as positive in 19 scans and negative in 11 scans with the same incidence of CEs which were significantly higher in positive than negative scans [cardiac dysfunction: 78.9% (15/19) vs. 27.2% (3/11); arrhythmic events: 65.5% (10/19) vs. 0% (0/11)]. In 19 positive scans, the three Ki parameters (Ki max, Ki mean and Ki volume) were significantly higher in scans for patients with arrhythmic events than in those without. Logistic regression analysis showed that the Ki volume alone was significantly associated with the risk of arrhythmic events. Our study suggests that Ki images may add value to SUV images for evaluating the risk of CEs in CS patients.

    DOI: 10.1038/s41598-021-82217-0

    Scopus

    PubMed

  • Nakajo M, Jinguji M, Tani A, Yano E, Hoo CK, Hirahara D, Togami S, Kobayashi H, Yoshiura T .  Machine learning based evaluation of clinical and pretreatment <sup>18</sup>F-FDG-PET/CT radiomic features to predict prognosis of cervical cancer patients. .  Abdominal radiology (New York)47 ( 2 ) 838 - 847   2021.11

     More details

    Language:English   Publisher:Abdominal Radiology  

    Purpose: To examine the usefulness of machine learning to predict prognosis in cervical cancer using clinical and radiomic features of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (CT) (18F-FDG-PET/CT). Methods: This retrospective study included 50 cervical cancer patients who underwent 18F-FDG-PET/CT before treatment. Four clinical (age, histology, stage, and treatment) and 41 18F-FDG-PET-based radiomic features were ranked and a subset of useful features for association with disease progression was selected based on decrease of the Gini impurity. Six machine learning algorithms (random forest, neural network, k-nearest neighbors, naive Bayes, logistic regression, and support vector machine) were compared using the areas under the receiver operating characteristic curve (AUC). Progression-free survival (PFS) was assessed using Cox regression analysis. Results: The five top predictors of disease progression were: stage, surface area, metabolic tumor volume, gray-level run length non-uniformity (GLRLM_RLNU), and gray-level non-uniformity for run (GLRLM_GLNU). The naive Bayes model was the best-performing classifier for predicting disease progression (AUC = 0.872, accuracy = 0.780, F1 score = 0.781, precision = 0.788, and recall = 0.780). In the naive Bayes model, 5-year PFS was significantly higher in predicted non-progression than predicted progression (80.1% vs. 9.1%, p < 0.001) and was only the independent factor for PFS in multivariate analysis (HR, 6.89; 95% CI, 1.92–24.69; p = 0.003). Conclusion: A machine learning approach based on clinical and pretreatment 18F-FDG PET-based radiomic features may be useful for predicting tumor progression in cervical cancer patients.

    DOI: 10.1007/s00261-021-03350-y

    Scopus

    PubMed

  • Nagano H, Takumi K, Nakajo M, Fukukura Y, Kumagae Y, Jinguji M, Tani A, Yoshiura T .  Dual-Energy CT-Derived Electron Density for Diagnosing Metastatic Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: Comparison With Conventional CT and FDG PET/CT Findings. .  AJR. American journal of roentgenology218 ( 1 ) 1 - 9   2021.11

     More details

    Language:English   Publisher:American Journal of Roentgenology  

    BACKGROUND. Accurate nodal staging is essential to guide treatment selection in patients with non-small cell lung cancer (NSCLC). To our knowledge, measurement of electron density (ED) using dual-energy CT (DECT) is unexplored for this purpose. OBJECTIVE. The purpose of our study was to assess the utility of ED from DECT in diagnosing metastatic mediastinal lymph nodes in patients with NSCLC in comparison with conventional CT and FDG PET/CT. METHODS. This retrospective study included 57 patients (36 men, 21 women; mean age, 68.4 } 8.9 [SD] years) with NSCLC and surgically resected mediastinal lymph nodes who underwent preoperative DECT and FDG PET/CT. The patients had a total of 117 resected mediastinal lymph nodes (33 metastatic, 84 nonmetastatic). Two radiologists independently reviewed the morphologic features of nodes on the 120-kVp images and also measured the iodine concentration (IC) and ED of nodes using maps generated from DECT data; consensus was reached for discrepancies. Two different radiologists assessed FDG PET/CT examinations in consensus for positive node uptake. Diagnostic performance was evaluated for individual and pairwise combinations of features. RESULTS. The sensitivity, specificity, and accuracy for nodal metastasis were 15.2%, 98.8%, and 75.2% for the presence of necrosis, respectively; 54.5%, 85.7%, and 76.9% for short-axis diameter greater than 8.5 mm; 63.6%, 73.8%, and 70.9% for long-axis diameter greater than 13.0 mm; 51.5%, 79.8%, and 71.8% for attenuation on 120-kVp images of 95.8 HU or less; 87.9%, 58.3%, and 66.7% for ED of 3.48 × 1023/cm3 or less; and 66.7%, 75.0%, and 72.6% for positive FDG uptake. Among pairwise combinations of features, accuracy was highest for the combination of ED and short-axis diameter (accuracy, 82.9%; sensitivity, 54.5%; specificity, 94.0%) and the combination of ED and positive FDG uptake (accuracy, 82.1%; sensitivity, 60.6%; specificity, 90.5%); these accuracies were greater than those for the individual features (p < .05). The remaining combinations exhibited accuracies ranging from 74.4% to 77.8%. Interobserver agreement analysis showed an intraclass correlation coefficient of 0.90 for ED. IC was not significantly different between metastatic and nonmetastatic nodes (p = .18) and was excluded from the diagnostic performance analysis. CONCLUSION. ED derived from DECT may help diagnose metastatic lymph nodes in NSCLC given decreased ED in metastatic nodes.

    DOI: 10.2214/AJR.21.26208

    Scopus

    PubMed

  • Ito K. .  <sup>18</sup>F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers .  Annals of Nuclear Medicine35 ( 11 ) 1253 - 1263   2021.11

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Objective: The prognostic value of treatment response in patients with non-small cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors (ICIs) shown by 18F-fludeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) results obtained with multiple types of PET scanners using standardized uptake value (SUV) harmonization was evaluated. Methods: Fifty-eight patients treated with ICIs who underwent 18F-FDG PET/CT examinations with nine types of PET scanners at six hospitals were enrolled. SUV harmonization of multiple PET scanner results was performed using the dedicated software packages “RAVAT” and “RC Tool for Harmonization”. Tumor response was assessed by change in sum of harmonized SUVmax, according to the European Organization for Research and Treatment of Cancer (EORTC5) or the SUV of up to five lesions normalized to lean body mass, according to the PET Response Criteria in Solid Tumors (PERCIST5) and immunotherapy-modified PERCIST (imPERCIST5) criteria. The correlation between tumor response according to those three definitions and overall survival (OS) was evaluated and compared to known prognostic factors. Results: One-year OS in responders and non-responders for harmonized EROTC5 was 86 and 32%, for harmonized PERCIST5 was 86 and 32%, and for harmonized imPERCIST5 was 80 and 30%, respectively (each p = 0.001). Univariate analysis showed that all response criteria remained as prognostic factors. However, there was an overlap for the categories stable metabolic disease (SMD) and progression metabolic disease (PMD) in survival curves using the PET treatment response criteria. Conclusion: In patients with NSCLC treated with ICIs, tumor response based on the harmonized response criteria was associated with OS. PET response criteria using harmonized metabolic parameters may be difficult to routinely employ in daily practice due to overlapping SMD and PMD, although may have a supporting role for determining prognosis.

    DOI: 10.1007/s12149-021-01667-8

    Scopus

    PubMed

  • Ito Kimiteru, Kitajima Kazuhiro, Toriihara Akira, Ishibashi Mana, Nakahara Tadaki, Daisaki Hiromitsu, Ohe Yuichiro, Honda Ryoichi, Kijima Takashi, Hasegawa Seiki, Nakajo Masatoyo .  異なる医療施設で使用されているPET/CT各装置から得られたSUVの調和による、非小細胞肺癌患者への抗PD-1治療モニタリングでの18F-FDG PET/CT検査(18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers) .  Annals of Nuclear Medicine35 ( 11 ) 1253 - 1263   2021.11異なる医療施設で使用されているPET/CT各装置から得られたSUVの調和による、非小細胞肺癌患者への抗PD-1治療モニタリングでの18F-FDG PET/CT検査(18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers)

     More details

    Language:English   Publisher:(一社)日本核医学会  

    免疫チェックポイント阻害薬(ICI)が投与された非小細胞肺癌(NSCLC)患者において、18F-FDG PET/CT検査よる治療効果判定で、PET装置の違いによるSUV値の変動を低減させるためSUV値を調和させることで、18F-FDG PET/CT検査で治療応答性予測が可能か検討した。2014年8月~2019年10月までの期間内に、国内医療施設6施設で免疫チェックポイント阻害薬(ICI)による治療前後に、9種類のPET装置で18F-FDG PET/CT検査が施行されたNSCLC患者のうち、選定基準を満たした患者58例(男性48例、女性10例、年齢54~88歳)を調査対象とした。SUVの調和には専用のソフトウェアを用いて行い、腫瘍応答性はSUV値を調和させたEuropean Organization for Research and Treatment of Cancer(EORTC5)、PET Response Criteria in Solid Tumors(PERCIST5)およびimmunotherapy-modified PERCIST(imPERCIST5)で評価した。その結果、SUV値を調和させたEROTC5、PERCIST5およびimPERCIST5によるレスポンダーおよびノンレスポンダーの1年全生存率(OS)は、それぞれ86%および32%、86%および32%、80%および30%であった。また、単変量解析により、これら全ての治療効果判定基準において予後予測能が認められたが、PET装置による治療効果判定基準を用いた生存曲線で、安定代謝(stable metabolic disease:SMD)と進行代謝(progression metabolic disease:PMD)のカテゴリーで重複が生じた。今回の後向き多施設共同研究により、SMDとPMDで重複が生じたため、本法を日常診療に導入することは難解と考えられたが、PET装置間のSUVを調和させることで施設間差が低減され、ICI治療を受けたNSCLC患者の治療応答性が予測され、OSと有意に関連することが明らかにされた。

  • Hozaka Y. .  Clinical utility and limitation of diagnostic ability for different degrees of dysplasia of intraductal papillary mucinous neoplasms of the pancreas using <sup>18</sup> F-fluorodeoxyglucose-positron emission tomography/ computed tomography .  Cancers13 ( 18 )   2021.9

     More details

    Language:English   Publisher:Cancers  

    The diagnostic value of18F-fluorodeoxyglucose (FDG) uptake in the management of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas remains unclear. This study aimed to assess the role of FDG uptake in the diagnosis of different degrees of dysplasia of IPMNs. We retrospectively analyzed the following three points in 84 patients with IPMNs: (1) risk factors to predict high-grade dysplasia (HGD) and invasive carcinoma (INV); (2) the relationship between FDG uptake and glucose transporter 1 (GLUT-1) expression; and (3) the relationship between FDG uptake and the presence of mural nodules. The histopathological diagnosis was low-grade dysplasia (LGD) in 43 patients, HGD in 16, and INV in 25. The maximum standardized uptake value (SUV-max) was significantly higher in INV than in LGD/HGD (p < 0.0001, p = 0.0136). The sensitivity and specificity to discriminate INV from LGD/HGD were 80.0% and 86.2%, respectively, using the receiver operator characteristic curve, when the optimal cutoff score of SUV-max was set at 4.03. Those values were not different between HGD and LGD. More than half of HGD patients had low GLUT-1 expression. Taken together, FDG-PET/CT is useful in distinguishing between non-invasive and invasive IPMN. Our results offer critical information that may determine surgical treatment strategies.

    DOI: 10.3390/cancers13184633

    Scopus

    PubMed

  • Eizuru Y, Nakajo M, Nakajo M, Shinohara N, Yoshiura T .  18F-FDG PET/CT Imaging of G-CSF-Producing Dedifferentiated Liposarcoma. .  Clinical nuclear medicine47 ( 1 ) e98 - e100   2021.6

     More details

    Language:English   Publisher:Clinical nuclear medicine  

    ABSTRACT: Granulocyte colony-stimulating factor (G-CSF)-producing tumors are malignant tumors associated with a poor prognosis, and G-CSF-producing liposarcoma is particularly rare. We report a case of G-CSF-producing dedifferentiated liposarcoma. 18F-FDG PET/CT showed abnormal 18F-FDG uptake throughout the bone marrow and in the primary site. When a diffuse bone marrow 18F-FDG uptake was observed on 18F-FDG PET/CT, G-CSF-producing dedifferentiated liposarcoma should be included in the differential diagnosis.

    DOI: 10.1097/RLU.0000000000003783

    Scopus

    PubMed

  • Kaida H, Kitajima K, Nakajo M, Ishibashi M, Matsunaga T, Minamimoto R, Hirata K, Nakatani K, Hung A, Hattori S, Yasuda T, Ishii K .  Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan. .  European journal of nuclear medicine and molecular imaging48 ( 11 ) 3666 - 3682   2021.5

     More details

    Language:English   Publisher:European Journal of Nuclear Medicine and Molecular Imaging  

    Purpose: To investigate the usefulness of the positron emission tomography response criteria in solid tumors 1.0 (PERCIST1.0) for predicting tumor response to neoadjuvant chemotherapy and prognosis and determine whether PERCIST improvements are necessary for esophageal squamous cell carcinoma (ESCC) patients. Patients and methods: We analyzed the cases of 177 ESCC patients and examined the association between PERCIST and their pathological responses. Associations of whole-PERCIST with progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and Cox proportional hazards model. To investigate potential PERCIST improvements, we used the survival tree technique to understand patients’ prognoses. Results: There were significant correlations between the pathologic response and PERCIST of primary tumor (p < 0.001). The optimal cutoff value of the primary tumors’ SULpeak response to classify pathologic responses was −50.0%. The diagnostic accuracy of SULpeak response was 87.3% sensitivity, 54.1% specificity, 68.9% accuracy, positive predictive value 60.5%, and negative predictive value 84.1%. Whole-PERCIST was significantly associated with PFS and OS. The survival tree results indicated that a high reduction of the whole SULpeak response was significantly correlated with the patients’ prognoses. The cutoff values for the separation of prognoses were − 52.5 for PFS and − 47.1% for OS. Conclusion: PERCIST1.0 can help predict tumor responses and prognoses. However, 18F-FDG-PET/CT tends to underestimate residual tumors in histopathological response evaluations. Modified PERCIST, in which the partial metabolic response is further classified by the SULpeak response (−50%), might be more appropriate than PERCIST1.0 for evaluating tumor responses and stratifying high-risk patients for recurrence and poor prognosis.

    DOI: 10.1007/s00259-021-05365-5

    Scopus

    PubMed

  • Nakajo M. .  A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article .  Medicine100 ( 15 ) e25494   2021.4

     More details

    Language:English   Publisher:Medicine  

    ABSTRACT: Recent breakthrough results from immune checkpoint inhibitors (ICIs) have paved the way to a new era of cancer immunotherapy, and have thus led to a paradigm shift of cancer treatment. In particular, inhibition of the antiprogrammed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis with ICI, including nivolumab and pembrolizumab, has been emerging as a novel treatment strategy for advanced gastric cancers. An accurate noninvasive assessment of the response to ICI is important for the management of patients with advanced or metastatic gastric cancer.To examine whether the European Organization for Research and Treatment of Cancer (EORTC) and PET Response Criteria in Solid Tumors (PERCIST) are valuable for predicting progression-free survival (PFS) in patients with advanced or metastatic gastric cancers treated with nivolumab.Six patients with advanced or metastatic gastric cancers who underwent 18F-FDG-PET/computed tomography (CT) scans before, and from 2 to 6 months after initiation of nivolumab therapy between September 2017 and August 2019, were evaluated retrospectively. The correlation between tumor progression and EORTC or PERCIST was assessed with the Fisher's exact test. The PFS was assessed with the Kaplan-Meier method.Two patients were alive without progression, and the remaining 4 patients exhibited tumor progression. Two patients without progression were classified as partial metabolic response (PMR) patients based on EORTC or PERCIST, while the other 4 patients with progression were classified as progressive metabolic disease (PMD) patients based on EORTC (P = .067), or stable metabolic disease (SMD) patients, or PMD patients based on PERCIST (P = .067).The mean and median PFS of all patients was 12.7 months (95% confidence interval [CI], 4.9-20.4 months) and 5 months (95%CI, 4.0-11.0 months). Two EORTC or PERCIST PMR patients showed significantly longer median PFS compared with 4 non-PMR patients (not reached vs 4.0 months, P = .044). Three PERCIST PMR or SMD patients also showed significantly longer median PFS compared with 3 PMD patients (not reached vs 4.0 months, P = .022). These results suggest that EORTC or PERCIST has the potential to predict PFS of patients with advanced or metastatic gastric cancers treated by nivolumab and further studies are needed to determine its value in larger study populations.

    DOI: 10.1097/MD.0000000000025494

    Scopus

    PubMed

  • 熊谷 雄一, 福倉 良彦, 中條 正豊, 吉浦 敬 .  特集1 地力が伸ばせる腹部画像診断:婦人科・腎・泌尿器 副腎−正常副腎の解剖・副腎皮質腺腫・褐色細胞腫の一般的な画像と診断のポイント− .  臨床画像37 ( 2 ) 194 - 205   2021.2特集1 地力が伸ばせる腹部画像診断:婦人科・腎・泌尿器 副腎−正常副腎の解剖・副腎皮質腺腫・褐色細胞腫の一般的な画像と診断のポイント−

     More details

    Publisher:メジカルビュー社  

    DOI: 10.18885/ci.0000000553

  • Nakajo M. .  Application of a machine learning approach to characterization of liver function using <sup>99m</sup>Tc-GSA SPECT/CT .  Abdominal Radiology46 ( 7 ) 3184 - 3192   2021

     More details

    Language:English   Publisher:Abdominal Radiology  

    Purpose: To assess the utility of a machine-learning approach for predicting liver function based on technetium-99 m-galactosyl serum albumin (99mTc-GSA) single photon emission computed tomography (SPECT)/CT. Methods: One hundred twenty-eight patients underwent a 99mTc-GSA SPECT/CT-based liver function evaluation. All were classified into the low liver-damage or high liver-damage group. Four clinical (age, sex, background liver disease and histological type) and 8 quantitative 99mTc-GSA SPECT/CT features (receptor index [LHL15], clearance index [HH15], liver-SUVmax, liver-SUVmean, heart-SUVmax, metabolic volume of liver [MVL], total lesion GSA [TL-GSA, liver-SUVmean × MVL] and SUVmax ratio [liver-SUVmax/heart-SUVmax]) were obtained. To predict high liver damage, a machine learning classification with features selection based on Gini impurity and principal component analysis (PCA) were performed using a support vector machine and a random forest (RF) with a five-fold cross-validation scheme. To overcome imbalanced data, stratified sampling was used. The ability to predict high liver damage was evaluated using a receiver operating characteristic (ROC) curve analysis. Results: Four indices (LHL15, HH15, heart SUVmax and SUVmax ratio) yielded high areas under the ROC curves (AUCs) for predicting high liver damage (range: 0.89–0.93). In a machine learning classification, the RF with selected features (heart SUVmax, SUVmax ratio, LHL15, HH15, and background liver disease) and PCA model yielded the best performance for predicting high liver damage (AUC = 0.956, sensitivity = 96.3%, specificity = 90.0%, accuracy = 91.4%). Conclusion: A machine-learning approach based on clinical and quantitative 99mTc-GSA SPECT/CT parameters might be useful for predicting liver function.

    DOI: 10.1007/s00261-021-02985-1

    Scopus

    PubMed

  • Nakajo M. .  Application of a Machine Learning Approach for the Analysis of Clinical and Radiomic Features of Pretreatment [<sup>18</sup>F]-FDG PET/CT to Predict Prognosis of Patients with Endometrial Cancer .  Molecular Imaging and Biology23 ( 5 ) 756 - 765   2021

     More details

    Language:English   Publisher:Molecular Imaging and Biology  

    Purpose: To examine the prognostic significance of pretreatment 2-deoxy-2-[18F]fluoro-d-glucose ([18F]-FDG) positron emission tomography (PET)-based radiomic features using a machine learning approach in patients with endometrial cancers. Procedures: Included in this retrospective study were 53 patients with endometrial cancers who underwent [18F]-FDG PET/X-ray computed tomography (CT) before treatment. Since two different PET scanners were used, post-reconstruction harmonization was performed for all PET parameters using the ComBat harmonization method. Four clinical (age, histological type, stage, and treatment method) and 40 [18F]-FDG PET-based radiomic features were ranked, and a subset of useful features was selected based on the decrease in the Gini impurity in terms of associations with disease progression. The machine learning algorithms (random forest, neural network, k-nearest neighbors (kNN), naive Bayes, logistic regression, and support vector machine) were compared using the areas under the receiver operating characteristic curve (AUC) and validated by the random sampling method. Progression-free survival (PFS) and overall survival (OS) were assessed by the Cox regression analysis. Results: The five best predictors of disease progression were coarseness, gray-level run length nonuniformity, stage, treatment method, and gray-level zone length nonuniformity. The kNN model obtained the best performance classifier for predicting the disease progression (AUC =0.890, accuracy =0.849, F1 score =0.848, precision =0.857, and recall =0.849). Coarseness which was the first ranked radiomic feature was selected for survival analyses, and only coarseness remained as a significant and independent factor for both PFS (hazard ratios (HR), 0.65; 95 % confidence interval [CI], 0.49–0.86; p=0.003) and OS (HR, 0.52; 95 % CI, 0.36–0.76; p<0.001) at multivariate Cox regression analysis. Conclusions: [18F]-FDG PET-based radiomic analysis using a machine learning approach may be useful for predicting tumor progression and prognosis in patients with endometrial cancers.

    DOI: 10.1007/s11307-021-01599-9

    Scopus

    PubMed

  • Kitajima K. .  Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using <sup>18</sup>F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST .  Japanese Journal of Radiology40 ( 1 ) 75 - 85   2021

     More details

    Language:English   Publisher:Japanese Journal of Radiology  

    Objective: In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response evaluation and prognosis prediction using standardized uptake value (SUV) harmonization of results obtained with various PET/CT scanners installed at different centers. Materials and methods: Malignant melanoma patients (n = 27) underwent FDG-PET/CT examinations before and again 3 to 9 months after therapy initiation (nivolumab, n = 21; pembrolizumab, n = 6) with different PET scanners at five hospitals. EORTC, PERCIST, and imPERCIST criteria were used to evaluate therapeutic response, then concordance of the results was assessed using Cohen’s κ coefficient. Log-rank and Cox methods were employed to determine progression-free (PFS) and overall (OS) survival. Results: Complete metabolic response (CMR)/partial metabolic response (PMR)/stable metabolic disease (SMD)/progressive metabolic disease (PMD) with harmonized EORTC, PERCIST, and imPERCIST was seen in 3/5/4/15, 4/5/3/15, and 4/5/5/13 patients, respectively. Nearly perfect concordance between each pair of criteria was noted (κ = 0.939–0.972). Twenty patients showed progression and 14 died from malignant melanoma after a median 19.2 months. Responders (CMR/PMR) showed significantly longer PFS and OS than non-responders (SMD/PMD) (harmonized EORTC: p < 0.0001 and p = 0.011; harmonized PERCIST: p < 0.0001 and p = 0.0012; harmonized imPERCIST: p < 0.0001 and p = 0.0012, respectively). Conclusions: All harmonized FDG-PET criteria (EORTC, PERCIST, imPERCIST) showed accuracy for response evaluation of ICI therapy and prediction of malignant melanoma patient prognosis. Additional studies to determine their value in larger study populations will be necessary.

    DOI: 10.1007/s11604-021-01174-w

    Scopus

    PubMed

  • O J.H. .  Quantitation of cancer treatment response by 2-[<sup>18</sup>F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™ .  EJNMMI Research11 ( 1 )   2021

     More details

    Language:English   Publisher:EJNMMI Research  

    Background: The aim of this study was to assess the reader variability in quantitatively assessing pre- and post-treatment 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) scans in a defined set of images of cancer patients using the same semi-automated analytical software (Auto-PERCIST™), which identifies tumor peak standard uptake value corrected for lean body mass (SULpeak) to determine [18F]FDG PET quantitative parameters. Methods: Paired pre- and post-treatment [18F]FDG PET/CT images from 30 oncologic patients and Auto-PERCIST™ semi-automated software were distributed to 13 readers across US and international sites. One reader was aware of the relevant medical history of the patients (readreference), whereas the 12 other readers were blinded to history but had access to the correlative images. Auto-PERCIST™ was set up to first automatically identify the liver and compute the threshold for tumor measurability (1.5 × liver mean) + (2 × liver standard deviation [SD]) and then detect all sites with SULpeak greater than the threshold. Next, the readers selected sites they believed to represent tumor lesions. The main performance metric assessed was the percent change in the SULpeak (%ΔSULpeak) of the hottest tumor identified on the baseline and follow-up images. Results: The intra-class correlation coefficient (ICC) for the %ΔSULpeak of the hottest tumor was 0.87 (95%CI: [0.78, 0.92]) when all reads were included (n = 297). Including only the measurements that selected the same target tumor as the readreference (n = 224), the ICC for %ΔSULpeak was 1.00 (95%CI: [1.00, 1.00]). The Krippendorff alpha coefficient for response (complete or partial metabolic response, versus stable or progressive metabolic disease on PET Response Criteria in Solid Tumors 1.0) was 0.91 for all reads (n = 380) and 1.00 including for reads with the same target tumor selection (n = 270). Conclusion: Quantitative tumor [18F]FDG SULpeak changes measured across multiple global sites and readers utilizing Auto-PERCIST™ show very high correlation. Harmonization of methods to single software, Auto-PERCIST™, resulted in virtually identical extraction of quantitative tumor response data from [18F]FDG PET images when the readers select the same target tumor.

    DOI: 10.1186/s13550-021-00754-1

    Scopus

  • Nakajo M. .  [<sup>18</sup>F]-FDG-PET/CT and [<sup>18</sup>F]-FAZA-PET/CT Hypoxia Imaging of Metastatic Thyroid Cancer: Association with Short-Term Progression After Radioiodine Therapy .  Molecular Imaging and Biology22 ( 6 ) 1609 - 1620   2020.12

     More details

    Language:English   Publisher:Molecular Imaging and Biology  

    DOI: 10.1007/s11307-020-01516-6

    Scopus

    PubMed

  • Nakajo M. .  Application of adrenal maximum standardized uptake value to <sup>131</sup>I-6β-iodomethyl-19-norcholesterol SPECT/CT for characterizing unilateral hyperfunctioning adrenocortical masses .  European Journal of Radiology133   109397   2020.12

     More details

    Language:English   Publisher:European Journal of Radiology  

    DOI: 10.1016/j.ejrad.2020.109397

    Scopus

    PubMed

  • Kitajima K, Kaida H, Nakatani K, Ishibashi M, Morita T, Nakajo M, Tamaki Y, Minamimoto R. .  Assessment of Tumor Response to Definitive Chemoradiotherapy and Prognosis Prediction in Patients With Esophageal Cancer Judged by PET Response Criteria in Solid Tumors: Multicenter Study in Japan .  Nucl Med Commun41 ( 5 ) 443 - 451   2020.5Assessment of Tumor Response to Definitive Chemoradiotherapy and Prognosis Prediction in Patients With Esophageal Cancer Judged by PET Response Criteria in Solid Tumors: Multicenter Study in Japan Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M. .  The clinical value of texture analysis of dual-time-point <sup>18</sup>F-FDG-PET/CT imaging to differentiate between <sup>18</sup>F-FDG-avid benign and malignant pulmonary lesions .  European Radiology30 ( 3 ) 1759 - 1769   2020.3

     More details

    Publisher:European Radiology  

    DOI: 10.1007/s00330-019-06463-7

    Scopus

    PubMed

  • Fukukura Y. .  Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma .  European Radiology30 ( 3 ) 1679 - 1689   2020.3

     More details

    Publisher:European Radiology  

    DOI: 10.1007/s00330-019-06517-w

    Scopus

    PubMed

  • Fukukura Y, Kumagae Y, Higashi R, Hakamada H, Nakajo M, Maemura K, Arima S, Yoshiura T. .  Extracellular Volume Fraction Determined by Equilibrium Contrast-Enhanced Dual-Energy CT as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma .  Eur Radiol30 ( 3 ) 1679 - 1689   2020.3Extracellular Volume Fraction Determined by Equilibrium Contrast-Enhanced Dual-Energy CT as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M, Jinguji M, Aoki M, Tani A, Sato M, Yoshiura T. .  The Clinical Value of Texture Analysis of Dual-Time-Point 18 F-FDG-PET/CT Imaging to Differentiate Between 18 F-FDG-avid Benign and Malignant Pulmonary Lesions .  Eur Radiol30 ( 3 ) 1759 - 1769   2020.3The Clinical Value of Texture Analysis of Dual-Time-Point 18 F-FDG-PET/CT Imaging to Differentiate Between 18 F-FDG-avid Benign and Malignant Pulmonary Lesions Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M, Kitajima K, Kaida H, Morita T, Minamimoto R, Ishibashi M, Yoshiura T. .  The Clinical Value of PERCIST to Predict Tumour Response and Prognosis of Patients With Oesophageal Cancer Treated by Neoadjuvant Chemoradiotherapy .  Clin Radiol.75 ( 1 ) 79.e9 - 79.e18.   2020.1The Clinical Value of PERCIST to Predict Tumour Response and Prognosis of Patients With Oesophageal Cancer Treated by Neoadjuvant Chemoradiotherapy Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M. .  The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy .  Clinical Radiology75 ( 1 ) 79.e9 - 79.e18   2020.1

     More details

    Publisher:Clinical Radiology  

    DOI: 10.1016/j.crad.2019.09.132

    Scopus

  • Kitajima K. .  Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: Multicenter study in Japan .  Nuclear Medicine Communications41 ( 5 ) 443 - 451   2020

     More details

    Publisher:Nuclear Medicine Communications  

    DOI: 10.1097/MNM.0000000000001168

    Scopus

    PubMed

  • Fukukura Y. .  Estimation of Extracellular Volume Fraction with Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients with Stage IV Pancreatic Ductal Adenocarcinoma .  Pancreas48 ( 10 ) 1360 - 1366   2019.11

     More details

  • Fukukura Y, Kumagae Y, Higashi R, Hakamada H, Nakajo M, Maemura K, Arima S, Yoshiura T. .  Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreatic Ductal Adenocarcinoma .  Pancreas48 ( 10 ) 1360 - 1366   2019.11Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreatic Ductal Adenocarcinoma Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M. .  A Pilot Study of Texture Analysis of Primary Tumor [<sup>18</sup>F]FDG Uptake to Predict Recurrence in Surgically Treated Patients with Non-small Cell Lung Cancer .  Molecular Imaging and Biology21 ( 4 ) 771 - 780   2019.8

     More details

    Publisher:Molecular Imaging and Biology  

    DOI: 10.1007/s11307-018-1290-z

    Scopus

    PubMed

  • Fukukura Y. .  CT and MRI features of undifferentiated carcinomas with osteoclast-like giant cells of the pancreas: a case series .  Abdominal Radiology44 ( 4 ) 1246 - 1255   2019.4

     More details

    Publisher:Abdominal Radiology  

    DOI: 10.1007/s00261-019-01958-9

    Scopus

    PubMed

  • Fukukura Y, Kumagae Y, Hirahara M, Hakamada H, Nagano H, Nakajo M, Kamimura K, Nakajo M, Higashi M, Yoshiura T. .  CT and MRI Features of Undifferentiated Carcinomas With Osteoclast-Like Giant Cells of the Pancreas: A Case Series .  Abdom Radiol (NY)44 ( 4 ) 1246 - 1255   2019.4CT and MRI Features of Undifferentiated Carcinomas With Osteoclast-Like Giant Cells of the Pancreas: A Case Series Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 中條 正豊 .  日中核医学短期交流報告書 .  核医学56 ( 1 ) 1 - 1   2019

     More details

    Publisher:一般社団法人 日本核医学会  

    DOI: 10.18893/kakuigaku.rp.1971

  • 北島 一宏, 南本 亮吾, 平田 健司, 山根 登茂彦, 甲斐田 勇人, 中條 正豊, 森田 敬裕, 中谷 航也, 石橋 愛 .  平成28・29 年度 ワーキンググループ報告:FDG-PET を用いた悪性腫瘍の治療効果判定 ~多施設共同研究~ .  核医学56 ( 1 ) 45 - 46   2019

     More details

    Publisher:一般社団法人 日本核医学会  

    DOI: 10.18893/kakuigaku.wgr.1977

  • Nakajo M. .  <sup>18</sup> F-FDG-PeT/CT features of primary tumours for predicting the risk of recurrence in thyroid cancer after total thyroidectomy: Potential usefulness of combination of the SuV-related, volumetric, and heterogeneous texture parameters .  British Journal of Radiology92 ( 1094 ) 20180620   2019

     More details

    Publisher:British Journal of Radiology  

    DOI: 10.1259/bjr.20180620

    Scopus

    PubMed

  • Nakajo M, Jinguji M, Shinaji T, Tani A, Nakabeppu Y, Nakajo M, Nakajo A, Natsugoe S, Yoshiura T. .  18F-FDG-PET/CT features of primary tumours for predicting the risk of recurrence in thyroid cancer after total thyroidectomy: potential usefulness of combination of the SUV-related, volumetric, and heterogeneous texture parameters. .  Br J Radiol   2018.1118F-FDG-PET/CT features of primary tumours for predicting the risk of recurrence in thyroid cancer after total thyroidectomy: potential usefulness of combination of the SUV-related, volumetric, and heterogeneous texture parameters.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M, Jinguji M, Shinaji T, Aoki M, Tani A, Nakabeppu Y, Nakajo M, Sato M, Yoshiura T. .  A Pilot Study of Texture Analysis of Primary Tumor [18F]FDG Uptake to Predict Recurrence in Surgically Treated Patients with Non-small Cell Lung Cancer. .  Mol Imaging Biol   2018.11A Pilot Study of Texture Analysis of Primary Tumor [18F]FDG Uptake to Predict Recurrence in Surgically Treated Patients with Non-small Cell Lung Cancer.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Kitajima K. .  Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST – multicenter study in Japan .  European Journal of Nuclear Medicine and Molecular Imaging45 ( 10 ) 1661 - 1671   2018.9

     More details

    Publisher:European Journal of Nuclear Medicine and Molecular Imaging  

    DOI: 10.1007/s00259-018-4008-1

    Scopus

    PubMed

  • Kitajima K, Nakatani K, Yamaguchi K, Nakajo M, Tani A, Ishibashi M, Hosoya K, Morita T, Kinoshita T, Kaida H, Miyoshi Y. .  Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan. .  Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.   2018.5Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M, Jinguji M, Shinaji T, Nakajo M, Aoki M, Tani A, Sato M, Yoshiura T. .  Texture analysis of 18F-FDG PET/CT for grading thymic epithelial tumours: usefulness of combining SUV and texture parameters. .  Br J Radiol91 ( 1083 ) 20170546   2018.1Texture analysis of 18F-FDG PET/CT for grading thymic epithelial tumours: usefulness of combining SUV and texture parameters.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Higo K, Kubota K, Miyanaga S, Miyata M, Nakajo M, Jinguji M, Ohishi M. .  Impairment of Iodine-123-Metaiodobenzylguanidine (123I-MIBG) Uptake in Patients with Pulmonary Artery Hypertension. .  Int Heart J59 ( 1 ) 112 - 119   2018.1Impairment of Iodine-123-Metaiodobenzylguanidine (123I-MIBG) Uptake in Patients with Pulmonary Artery Hypertension.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Higo Kenjuro, Kubota Kayoko, Miyanaga Sunao, Miyata Masaaki, Nakajo Masatoyo, Jinguji Megumi, Ohishi Mitsuru .  肺動脈高血圧症患者におけるヨード123-メタヨードベンジルグアニジン(123I-MIBG)の取り込み低下(Impairment of Iodine-123-Metaiodobenzylguanidine(123I-MIBG) Uptake in Patients with Pulmonary Artery Hypertension) .  International Heart Journal59 ( 1 ) 112 - 119   2018.1肺動脈高血圧症患者におけるヨード123-メタヨードベンジルグアニジン(123I-MIBG)の取り込み低下(Impairment of Iodine-123-Metaiodobenzylguanidine(123I-MIBG) Uptake in Patients with Pulmonary Artery Hypertension)

     More details

    Publisher:(一社)インターナショナルハートジャーナル刊行会  

    肺高血圧症(PH)患者では肺の123-メタヨードベンジルグアニジン(123I-MIBG)取り込みが低下しているとの仮説を立て、PH患者の肺123I-MIBG取り込みを評価し、心エコー検査や右心カテーテル法で得られた各指標と比較検討した。2003年12月〜2014年12月に123I-MIBGシンチを施行されたPH患者21例と、性別・年齢を一致させた対照8例を対象とした。心エコー、6分間歩行試験、B型ナトリウム利尿ペプチド測定、肺機能検査、右心カテーテル法を施行した。PH患者を慢性血栓塞栓性肺高血圧症(CTEPH)9例(男性2例、女性7例、平均69.1±7.5歳)と肺動脈高血圧症(PAH)12例(男性3例、女性9例、平均54.1±13.4歳)に分けた。平均肺動脈圧はCTEPH群が37.7±6.8mmHg、PAH群が32.3±5.3mmHgで有意差はなかった。両群間でその他の血行動態パラメーターに有意差はなかった。123I-MIBGの肺取り込みはPAH群ではearly image(EI)1.54±0.18、delayed image(DI) 1.41±0.16で、CTEPH群のEI 2.17±0.25、DI 1.99±0.20、対照群のEI2.32±0.27、DI 1.92±0.19よりも有意に低かった。PAH患者では肺血管内皮機能が低下している可能性が示唆された。

  • Higo Kenjuro, Kubota Kayoko, Miyanaga Sunao, Miyata Masaaki, Nakajo Masatoyo, Jinguji Megumi, Ohishi Mitsuru .  Impairment of Iodine-123-Metaiodobenzylguanidine (<sup>123</sup>I-MIBG) Uptake in Patients with Pulmonary Artery Hypertension .  International Heart Journal59 ( 1 ) 112 - 119   2018

     More details

    Publisher:一般社団法人 インターナショナル・ハート・ジャーナル刊行会  

    <p>According to recent studies, lung uptake of iodine-123-metaiodobenzylguanidine (<sup>123</sup>I-MIBG) is impaired in many lung diseases and low lung uptake of <sup>123</sup>I-MIBG suggests endothelial dysfunction of the pulmonary artery. <sup>123</sup>I-MIBG scintigraphy in patients with pulmonary hypertension (PH) has not yet been clinically evaluated. We hypothesized that the lung uptake of <sup>123</sup>I-MIBG is reduced in patients with PH and differs among PH subtypes. The purpose of the present study was to analyze the lung uptake of <sup>123</sup>I-MIBG in patients with PH and compare it with the data obtained by echocardiography or right heart catheterization. <sup>123</sup>I-MIBG scintigraphy was performed in 286 consecutive patients from 2003 to 2014. We enrolled 21 patients with PH and 8 control patients. The 21 patients with PH were categorized into those with pulmonary artery hypertension (PAH, <i>n</i> = 12) and those with chronic thromboembolic pulmonary hypertension (CTEPH, <i>n</i> = 9). The mean pulmonary artery pressure was not significantly different between patients with CTEPH and PAH (37.7 ± 6.8 versus 32.3 ± 5.3 mmHg respectively; <i>P</i> = 0.054). There were no significant differences in any other hemodynamic parameters between the two groups. The lung uptake of <sup>123</sup>I-MIBG in PAH patients (early image: 1.54 ± 0.18, delayed image: 1.41 ± 0.16) was significantly lower than that of CTEPH patients (early image: 2.17 ± 0.25, <i>P</i> < 0.0001; delayed image: 1.99 ± 0.20, <i>P</i> = 0.0001, adjusted for age and World Health Organization classification) and controls (early image: 2.32 ± 0.27, <i>P</i> = 0.0007; delayed image: 1.92 ± 0.19, <i>P</i> = 0.0007). In conclusion, we found for the first time that the lung uptake of <sup>123</sup>I-MIBG in patients with PAH is lower than that in patients with CTEPH and controls.</p>

    DOI: 10.1536/ihj.16-629

    Scopus

    PubMed

  • Nakajo M. .  Texture analysis of <sup>18</sup>F-FDG peT/CT for grading thymic epithelial tumours: usefulness of combining SuV and texture parameters .  British Journal of Radiology91 ( 1083 ) 20170546   2018

     More details

    Publisher:British Journal of Radiology  

    DOI: 10.1259/bjr.20170546

    Scopus

    PubMed

  • Nakajo M. .  Texture analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal tumors: efficacy of combining SUV and texture parameters .  Abdominal Radiology42 ( 12 ) 2882 - 2889   2017.12

     More details

    Publisher:Abdominal Radiology  

    DOI: 10.1007/s00261-017-1207-3

    Scopus

    PubMed

  • Nakajo M, Kajiya Y, Tani A, Jinguji M, Nakajo M, Kitazono M, Yoshiura T. .  A pilot study for texture analysis of 18F-FDG and 18F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery. .  Eur J Nucl Med Mol Imaging44 ( 13 ) 2158 - 2168   2017.12A pilot study for texture analysis of 18F-FDG and 18F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M, Jinguji M, Nakajo M, Shinaji T, Nakabeppu Y, Fukukura Y, Yoshiura T. .  Texture analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal tumors: efficacy of combining SUV and texture parameters. .  Abdom Radiol (NY)42 ( 12 ) 2882 - 2889   2017.12Texture analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal tumors: efficacy of combining SUV and texture parameters.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M. .  A pilot study for texture analysis of <sup>18</sup>F-FDG and <sup>18</sup>F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery .  European Journal of Nuclear Medicine and Molecular Imaging44 ( 13 ) 2158 - 2168   2017.12

     More details

    Publisher:European Journal of Nuclear Medicine and Molecular Imaging  

    DOI: 10.1007/s00259-017-3787-0

    Scopus

    PubMed

  • Kitajima K. .  Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: An update .  Nagoya Journal of Medical Science79 ( 4 ) 527 - 543   2017.11

     More details

    Publisher:Nagoya Journal of Medical Science  

    DOI: 10.18999/nagjms.79.4.527

    Scopus

    PubMed

  • Kitajima K, Nakajo M, Kaida H, Minamimoto R, Hirata K, Tsurusaki M, Doi H, Ueno Y, Sofue K, Tamaki Y, Yamakado K. .  Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update. .  Nagoya J Med Sci79 ( 4 ) 527 - 543   2017.11Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 加治屋 より子, 谷 淳至, 南立 亮, 仮屋 圭佑, 神宮司 メグミ, 中條 正豊, 西俣 寛人, 福永 秀敏, 中條 政敬, 吉浦 敬 .  PET検診がん発見率と年代や性別、受診回数との関連性 どのような人がFDG-PET検診を受けるとよいか .  臨床放射線62 ( 9 ) 1157 - 1163   2017.9PET検診がん発見率と年代や性別、受診回数との関連性 どのような人がFDG-PET検診を受けるとよいか

     More details

    Publisher:金原出版(株)  

    PET検診6256件を対象に、癌発見率と年代や性別、受診回数との関連を検討した。実受診者数は4898人で、うち複数回受検者が710人、内訳は男3562人・女2694人・平均年齢58.0歳であった。162件(167の癌病変、重複癌3人、3重複癌1人を含む)の癌が発見され、癌発見率は延べで3.3%、初回で3.0%、癌病変発見率は延べで2.7%、初回で3.1%、2回目で1.4%であった。男女あわせた年代別発見率の推移では、加齢により有意に癌の発見率が上昇していた。男女別で50歳を境とした2群で年齢と発見率を比較したところ、男性では50歳以上で50歳未満に比べて発見率が高く、女性では有意差はなかった。初回受診者のみの病変発見率をみると、全体と同様に男性で発見率が高く、加齢によりその傾向が顕著であったが、各年代での発見率がより高かった。以上、PET癌検診発見率は受検者の年齢や性別、特に年齢に大きく影響されると考えられた。

  • Jinguji M. .  Thymic involution after radioiodine therapy for graves disease: Relationships with serum thyroid hormones and TRAb .  Journal of the Endocrine Society1 ( 7 ) 852 - 860   2017.7

     More details

    Publisher:Journal of the Endocrine Society  

    DOI: 10.1210/js.2017-00182

    Scopus

    PubMed

  • Jinguji M, Nakajo M, Nakajo M, Koriyama C, Yoshiura T. .  Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb. .  J Endocr Soc1 ( 7 ) 852 - 860   2017.6Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M. .  A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT .  Abdominal Radiology42 ( 4 ) 1210 - 1221   2017.4

     More details

    Publisher:Abdominal Radiology  

    DOI: 10.1007/s00261-016-0987-1

    Scopus

    PubMed

  • Umanodan T. .  ADC histogram analysis for adrenal tumor histogram analysis of apparent diffusion coefficient in differentiating adrenal adenoma from pheochromocytoma .  Journal of Magnetic Resonance Imaging45 ( 4 ) 1195 - 1203   2017.4

     More details

    Publisher:Journal of Magnetic Resonance Imaging  

    DOI: 10.1002/jmri.25452

    Scopus

    PubMed

  • Umanodan T, Fukukura Y, Kumagae Y, Shindo T, Nakajo M, Takumi K, Nakajo M, Hakamada H, Umanodan A, Yoshiura T. .  ADC histogram analysis for adrenal tumor histogram analysis of apparent diffusion coefficient in differentiating adrenal adenoma from pheochromocytoma. .  J Magn Reson Imaging. 45 ( 4 ) 1195 - 1203   2017.4ADC histogram analysis for adrenal tumor histogram analysis of apparent diffusion coefficient in differentiating adrenal adenoma from pheochromocytoma.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M, Kajiya Y, Tani A, Jinguji M, Nakajo M, Nihara T, Fukukura Y, Yoshiura T. .  A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT. .  Abdom Radiol (NY)42 ( 4 ) 1210 - 1221   2017.4A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M. .  Current clinical status of <sup>18</sup>F-FLT PET or PET/CT in digestive and abdominal organ oncology .  Abdominal Radiology42 ( 3 ) 951 - 961   2017.3

     More details

    Publisher:Abdominal Radiology  

    DOI: 10.1007/s00261-016-0947-9

    Scopus

    PubMed

  • Nakajo M, Kajiya Y, Jinguji M, Nakabeppu Y, Nakajo M, Nihara T, Yoshiura T. .  Current clinical status of 18F-FLT PET or PET/CT in digestive and abdominal organ oncology. .  Abdom Radiol (NY)42 ( 3 ) 951 - 961   2017.3Current clinical status of 18F-FLT PET or PET/CT in digestive and abdominal organ oncology.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M. .  Texture analysis of <sup>18</sup>F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy .  European Journal of Nuclear Medicine and Molecular Imaging44 ( 2 ) 206 - 214   2017.2

     More details

    Publisher:European Journal of Nuclear Medicine and Molecular Imaging  

    DOI: 10.1007/s00259-016-3506-2

    Scopus

    PubMed

  • Nakajo M, Jinguji M, Nakabeppu Y, Nakajo M, Higashi R, Fukukura Y, Sasaki K, Uchikado Y, Natsugoe S, Yoshiura T. .  Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy. .  Eur J Nucl Med Mol Imaging44 ( 2 ) 206 - 214   2017.2Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M, Kajiya Y, Tani A, Jinguji M, Nakajo M, Yoshiura T. .  FLT-PET/CT diagnosis of primary and metastatic nodal lesions of gastric cancer: comparison with FDG-PET/CT. .  Abdom Radiol (NY)41 ( 10 ) 1891 - 1898   2016.10FLT-PET/CT diagnosis of primary and metastatic nodal lesions of gastric cancer: comparison with FDG-PET/CT.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Werner RA, Kroiss M, Nakajo M, Mügge DO, Hahner S, Fassnacht M, Schirbel A, Bluemel C, Higuchi T, Papp L, Zsótér N, Buck AK, Bundschuh RA, Lapa C. .  Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography. .  Endocrine53 ( 3 ) 791 - 800   2016.5Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Jinguji M, Kajiya Y, Nakajo M, Nakajo M, Yoshiura T. .  Increased 18F-FDG Uptake in the Spleen and Multiple Lymph Nodes in Dengue Fever. .  Clin Nucl Med41 ( 5 ) e255 - e256   2016.5Increased 18F-FDG Uptake in the Spleen and Multiple Lymph Nodes in Dengue Fever.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M, Nakajo M, Nakayama H, Jinguji M, Nakabeppu Y, Higashi M, Nakamura Y, Sato M, Yoshiura T .  Dexamethasone Suppression FDG PET/CT for Differentiating between True- and False-Positive Pulmonary and Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer: A Pilot Study of FDG PET/CT after Oral Administration of Dexamethasone. .  Radiology279 ( 1 ) 246 - 253   2016.4Dexamethasone Suppression FDG PET/CT for Differentiating between True- and False-Positive Pulmonary and Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer: A Pilot Study of FDG PET/CT after Oral Administration of Dexamethasone.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Jinguji M, Nakajo M, Nakajo M, Nakabeppu Y, Yoshiura T. .  Vasovagal-related stress immediately before FDG injection may increase bilateral adrenal FDG uptake. .  Br J Radiol89 ( 1061 ) 20150950   2016.3Vasovagal-related stress immediately before FDG injection may increase bilateral adrenal FDG uptake.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo M, Nakajo M, Jinguji M, Fukukura Y, Nakabeppu Y, Tani A, Yoshiura T .  The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT. .  Br J Radiol   2015.9The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo., Jinguji M., Fukukura Y., Kajiya Y., Tani A., Nakajo M., Nakabeppu Y., Arimura H., Nishio Y., Yoshiura T. .  FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumors. .  Eur Radiol.2015 Apr 30.[Epub ahead of print]   2015.4FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumors.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Kurosawa H, Sakurai K, Hasegawa H, Uchida K, Kasahara H, Minamizawa T, Nakajo Masatoyo, Nakajo M. .  Comparison of radioactive iodide uptake in the rat thyroid between oral and intravenous bolus administration. .  Ann Nucl Med. 2014 Oct 5. [Epub ahead of print]28 ( 10 ) 986 - 993   2014.12Comparison of radioactive iodide uptake in the rat thyroid between oral and intravenous bolus administration.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, Kayano D, Fukuoka M, Inaki A, Toratani A, Okamoto S, Shiga T, Ito YM, Nakajo Masatoyo, Nakajo M, Kinuya S. .  Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry .  Endocr J. 61 ( 12 ) 1171 - 1180   2014.12Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registryReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Nakajo M, Kajiya Y, Goto Y, Jinguji M, Tanaka S, Fukukura Y, Tani A, Higashi M. .  Correlations of 18F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci. .  Eur Radiol 24 ( 12 ) 3199 - 3209   2014.12Correlations of 18F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo., Nakajo M., Fukukura Y., Jinguji M., Shindo T., Nakabeppu Y., Kamimura K., Yoneyama T., Takumi K., Yoshiura T. .  Diagnostic performances of FDG-PET/CT and diffusion-weighted imaging indices for differentiating benign pheochromocytoma from other benign adrenal tumors. .  Abdom Imaging. 2014 Nov 11. [Epub ahead of print]   2014.11Diagnostic performances of FDG-PET/CT and diffusion-weighted imaging indices for differentiating benign pheochromocytoma from other benign adrenal tumors. Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Baba Y, Hayashi S, Ikeda S, Jinguji M, Nakajo Masatoyo, Nakajo M. .  Evaluation of Split Renal Function Before and After Renal Arterial Embolization for Angiomyolipoma Using Absolute Ethanol. .  Cardiovasc Intervent Radiol 37 ( 5 ) 1220 - 1225   2014.10Evaluation of Split Renal Function Before and After Renal Arterial Embolization for Angiomyolipoma Using Absolute Ethanol.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Nakajo Masayuki, Kajiya Y, et al. .  Diagnostic performance of 18F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: Comparison with 18F-fluorodeoxyglucose PET/CT .  Eur J Nucl Med Mol Imaging40 ( 8 ) 1223 - 1232   2013.8Diagnostic performance of 18F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: Comparison with 18F-fluorodeoxyglucose PET/CTReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Nakajo Masayuki, Jinguji M, et al. .  Diagnosis of metastases from postoperative differentiated thyroid cancer: Comparison between F-18-fluorodeoxyglucose and F-18-fluorothymidine PET/CT studies .  Radiology267 ( 3 ) 891 - 901   2013.6Diagnosis of metastases from postoperative differentiated thyroid cancer: Comparison between F-18-fluorodeoxyglucose and F-18-fluorothymidine PET/CT studiesReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Nakajo Masayuki, Kajiya Y, et al. .  High FDG and low FLT uptake in a thyroid papillary carcinoma incidentally discovered by FDG PET/CT .  Clin Nucl Med37 ( 6 ) 607 - 608   2012.6High FDG and low FLT uptake in a thyroid papillary carcinoma incidentally discovered by FDG PET/CTReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Nakajo Masayuki, Yoriko Kajiya Y, et al. .  FDG-PET/CT and Diffusion-Weighted Imaging of Head and Neck Squamous Cell Carcinoma: Comparison of Prognostic Significance between Primary Tumor Standardized Uptake Value and Apparent Diffusion Coefficient .  Clin Nucl Med37 ( 5 ) 475 - 480   2012.5FDG-PET/CT and Diffusion-Weighted Imaging of Head and Neck Squamous Cell Carcinoma: Comparison of Prognostic Significance between Primary Tumor Standardized Uptake Value and Apparent Diffusion CoefficientReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Nakayama H, Sato M, et al. .  FDG PET/CT finding of benign metastasizing leiomyoma of the lung .  Acta Radiologica Short Reports1 ( 3 ) 13   2012.4FDG PET/CT finding of benign metastasizing leiomyoma of the lungReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Kajiya Yoriko, Tani A, et al. .  (18)FDG PET for grading malignancy in thymic epithelial tumors: Significant differences in (18)FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: Preliminary study. .  Eur J Radiol81 ( 1 ) 146 - 151   2012.1(18)FDG PET for grading malignancy in thymic epithelial tumors: Significant differences in (18)FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: Preliminary study.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Nakajo Masayuki, Kajiya Y, et al. .  A black adrenal adenoma difficult to be differentiatedfrom a malignant adrenal tumor by CT, MRI, scintigraphyand FDG PET/CT examinations .  Ann Nucl Med25 ( 10 ) 812 - 817   2011.12A black adrenal adenoma difficult to be differentiatedfrom a malignant adrenal tumor by CT, MRI, scintigraphyand FDG PET/CT examinationsReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Nakajo Masayuki, Tani A, et al. .  Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas .  Eur Radiol 21 ( 11 ) 2396 - 2407   2011.11Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomasReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Kajiya Y, Kaneko T, et al. .  FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. .  Eur J Nucl Med Mol Imaging37 ( 11 ) 2011 - 2020   2010.11FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Jinnouchi S, Hamada N, et al. .  FDG PET/CT findings of mesenchymalhamartoma of the liver in an adult .  Clin Nucl Med34 ( 5 ) 327 - 329   2009.5FDG PET/CT findings of mesenchymalhamartoma of the liver in an adultReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Jinnouchi S, Tashiro Y, et al. .  Effect of clinicopathological factors on visibility of colorectal polyps with FDG PET. .  AJR Am J Roentgenol192 ( 3 ) 754 - 760   2009.3Effect of clinicopathological factors on visibility of colorectal polyps with FDG PET. Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Jinnouchi S, Arimura H, et al .  FDG PET/CT of urachalabcess .  Clin Nucl Med33 ( 8 ) 579 - 581   2008.8FDG PET/CT of urachalabcessReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Jinnouchi S, Fukukura Y, et al. .  The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and asscocitaedextrapancreatic autoimmune lesions. .  Eur J Nucl Med Mol Imaging34 ( 12 ) 2088 - 2095   2007.12The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and asscocitaedextrapancreatic autoimmune lesions.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Jinnouchi S, Inoue H, et al. .  FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment. .  Clin Nucl Med32 ( 10 ) 775 - 778   2007.10FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Jinnouchi S, Tanabe H, et al. .  18F-fluorodeoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis. .  J Comput Assist Tomogr.31 ( 4 ) 539 - 543   2007.818F-fluorodeoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Jinnouchi S, Noguchi M, et al. .  FDG-PET and PET/CT monitoring of autoimmune pancreatitis asscocitaed with extrapancreatic autoimmune disease. .  Clin Nucl Med32 ( 4 ) 282 - 285   2007.4FDG-PET and PET/CT monitoring of autoimmune pancreatitis asscocitaed with extrapancreatic autoimmune disease.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Jinnouchi S, Tateno R, Nakajo Masayuki. .  18F-FDG-PET findings of a right subphrenic foreign-body granuloma. .  Ann Nucl Med20 ( 8 ) 553 - 556   2006.1018F-FDG-PET findings of a right subphrenic foreign-body granuloma.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Ohkubo K, Fukukura Y, Nandate T, Nakajo Msayuki. .  Treatment of recurrent chordomas by percutaneous ethanol injection therapy and radiation therapy. .  Acta Radiol47 ( 3 ) 297 - 300   2006.4Treatment of recurrent chordomas by percutaneous ethanol injection therapy and radiation therapy. Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Ohkubo K, Fukukura Y, Nandate T, Nakajo Msayuki. .  Embolization of spontaneous rupture of an aneurysm of the ovarian artery supplying the uterus with fibroids. .  Acta Radiol46 ( 8 ) 887 - 890   2005.12Embolization of spontaneous rupture of an aneurysm of the ovarian artery supplying the uterus with fibroids.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Ohkubo K, Nadante T, et al. .  Primary synovial sarcoma of the sternum: computed and magnetic resonance imaging findigs. .  Radiat Med23 ( 3 ) 208 - 212   2005.5Primary synovial sarcoma of the sternum: computed and magnetic resonance imaging findigs. Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nakajo Masatoyo, Ohkubo K, Nadante T, et al. .  Intraosseous epidermal cyst of the distal phalanx of the thumb: radiographic and magnetic resonance imaging findings. .  Radiat Med23 ( 2 ) 128 - 132   2005.3Intraosseous epidermal cyst of the distal phalanx of the thumb: radiographic and magnetic resonance imaging findings.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

▼display all

MISC

  • The Global Reading Room: Nuclear Medicine Imaging of a Diabetic Foot Ulcer

    Israel O., Nakajo M., Nunes R.F., Packard A.T.

    American Journal of Roentgenology   219 ( 4 )   681 - 682   2022.10

     More details

    Language:Japanese   Publisher:American Journal of Roentgenology  

    DOI: 10.2214/AJR.21.27251

    Scopus

    PubMed

  • Recent topics of the clinical utility of PET/MRI in oncology and neuroscience(タイトル和訳中)

    Nakamoto Yuji, Kitajima Kazuhiro, Toriihara Akira, Nakajo Masatoyo, Hirata Kenji

    Annals of Nuclear Medicine   36 ( 9 )   798 - 803   2022.9

     More details

    Language:English   Publisher:(一社)日本核医学会  

  • 【地力が伸ばせる腹部画像診断:婦人科・腎・泌尿器】副腎 正常副腎の解剖・副腎皮質腺腫・褐色細胞腫の一般的な画像と診断のポイント

    熊谷 雄一, 福倉 良彦, 中條 正豊, 吉浦 敬

    臨床画像   37 ( 2 )   194 - 205   2021.2

     More details

    Publisher:(株)メジカルビュー社  

    <文献概要>・正常副腎は,CT・MRIで腎頭側に逆Y字型としてみられる。・副腎偶発腫の大半を皮質腺腫が占める。皮質腺腫の診断手順を熟知することは重要である。皮質腺腫の診断は主に,腫瘤の脂質の有無と造影パターンによる2つのアプローチによりなされる。・褐色細胞腫が疑われる場合,副腎髄質シンチグラフィ(123I-MIBG)を積極的に行う。

  • Correction to: [18F]-FDG-PET/CT and [18F]-FAZA-PET/CT Hypoxia Imaging of Metastatic Thyroid Cancer: Association with Short-Term Progression after Radioiodine Therapy (Molecular Imaging and Biology, (2020), 22, 6, (1609-1620), 10.1007/s11307-020-01516-6)

    Nakajo M.

    Molecular Imaging and Biology   22 ( 6 )   1621   2020.12

     More details

    Publisher:Molecular Imaging and Biology  

    DOI: 10.1007/s11307-020-01525-5

    Scopus

    PubMed

  • 【Q&Aでまとめる! 予後予測・治療効果予測の画像検査】頭頸部 甲状腺癌に対する外科療法後の高リスク再発を予測する画像検査法は何か?

    中條 正豊

    臨床放射線   65 ( 8 )   803 - 806   2020.8

     More details

    Publisher:金原出版(株)  

  • 【核医学とAI】腫瘍PETイメージングにおけるtexture解析の臨床応用について

    中條 正豊

    Rad Fan   17 ( 11 )   43 - 45   2019.9

     More details

    Publisher:(株)メディカルアイ  

    18F-FDG-PET/CTにおけるtexture解析は、腫瘍内の不均一性を評価する方法であり、腫瘍の悪性度評価や治療効果判定などに有用と考えられる。Texture解析方法の標準化などを含めて、日常臨床においてtexture解析を活用するには、様々な課題があるが、今後、人工知能(AI)を用いた研究の発展に期待される。(著者抄録)

  • 平成28・29年度ワーキンググループ報告 FDG-PETを用いた悪性腫瘍の治療効果判定 多施設共同研究

    北島 一宏, 南本 亮吾, 平田 健司, 山根 登茂彦, 甲斐田 勇人, 中條 正豊, 森田 敬裕, 中谷 航也, 石橋 愛

    核医学   56 ( 1 )   45 - 46   2019

     More details

    Publisher:(一社)日本核医学会  

  • 【副腎の画像診断・IVR:診断に必要な基礎から臨床まで】副腎疾患の核医学診断

    神宮司 メグミ, 中條 正豊, 中條 政敬, 谷 淳至, 吉浦 敬

    臨床画像   34 ( 3 )   306 - 316   2018.3

     More details

    Publisher:(株)メジカルビュー社  

    副腎の画像診断においては、代謝機能を反映する核医学画像は古くから非常に重要な役割を果たしてきた。最近ではSPECTやPETの核医学画像と形態画像のCTやMRIとの融合も容易となり、よりわかりやすい画像が得られるようになってきた。(著者抄録)

  • 消化器癌管理におけるFDG-PET/CTイメージングの現状と今後の役割 最新情報(Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update)

    Kitajima Kazuhiro, Nakajo Masatoyo, Kaida Hayato, Minamimoto Ryogo, Hirata Kenji, Tsurusaki Masakatsu, Doi Hiroshi, Ueno Yoshiko, Sofue Keitaro, Tamaki Yukihisa, Yamakado Koichiro

    Nagoya Journal of Medical Science   79 ( 4 )   527 - 543   2017.11

     More details

    Publisher:名古屋大学医学部  

▼display all

Presentations

  • Nakajo M, Jinguji M, Tani A, Nagano H, Nakabeppu Y, Nakajo M, Yoshiura T   Texture analysis of 18F-FDG PET/CT for predicting the malignant nature in thymic epithelial tumors   International conference

    Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. 

     More details

    Event date: 2017.6

    Language:English   Presentation type:Poster presentation  

    Venue:Denver, USA  

  • Nakajo M, Jinguji M, Tani A, Kajiya Y, Nakajo M, Yoshiura T   Texture analysis of 18F-FDG and 18F-FLT PET/CT scans to predict prognosis of patients with colorectal cancer treated by surgery   International conference

    Asian Nuclear Medicine Academic Forum 

     More details

    Event date: 2017.5

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Shanghai, China  

  • Masatoyo Nakajo, M Jinguji, Y Nakabeppu , R Higashi, Y Fukukura, T Yoshiura   Assessment of primary tumor FDG PET/CT texture features for predicting tumor response to chemoradiotherapy and prognosis of patients with esophageal cancer   International conference

    RSNA 

     More details

    Event date: 2016.11 - 2016.12

    Language:English   Presentation type:Poster presentation  

    Venue:Chicago, USA  

  • Masatoyo Nakajo   Comparison of FDG-PET/CT and diffusion-weighted imaging indexes for differentiation between benign pheochromocytomas and other benign adrenal tumors.   Invited International conference

    3th Asian Nuclear Medicine Board (ANMB) Examination 

     More details

    Event date: 2016.7

    Language:English   Presentation type:Poster presentation  

    Venue:Shenyang, China  

  • 20. Masatoyo Nakajo, Y Kajiya, A Tani, M Jinguji, M Nakajo, Y Fukukura, T Yoshiura   Prognostic value of FLT-PET/CT in patients with pancreatic cancer: comparison with FDG-PET/CT.   International conference

    63th Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 

     More details

    Event date: 2016.6

    Language:English   Presentation type:Oral presentation (general)  

    Venue:San Diego, USA  

  • Masatoyo Nakajo, Y Kajiya, A Tani, M Jinguji, Y Nakabeppu, M Nakajo, S Shimaoka, T Nihara, S Tanaka, T Yoshiura   Diagnostic performance of 18F-fluorothymidine PET/CT for primary gastric cancer and its lymph node metastasis: Comparison with 18F-fluorodeoxyglucose PET/CT.   International conference

    Annual Congress of the European Association of Nuclear Medicine (EANM’15) 

     More details

    Event date: 2015.10

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Hamburg, Germany  

  • Masatoyo Nakajo, H Nakayama, M Jinguji, Y Nakaeppu, M Nakajo, T Yoshiura   Dexamethasone suppression FDG-PET/CT for differentiating between true and false positive mediastinal lymph node metastases in non-small cell lung cancer.   International conference

    Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. 

     More details

    Event date: 2015.6

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Baltimore, USA.  

  • 中條正豊, 神宮司メグミ, 中別府良昭, 中條 政敬, 吉浦 敬   原発性肺癌のリンパ節転移診断におけるステロイド負荷FDG PET/CTの有用性の検討  

    第54回日本核医学学術総会  第54回日本核医学学術総会

     More details

    Event date: 2014.11

    Language:Japanese  

    Venue:大阪  

    国内学会

  • Masatoyo Nakajo, Megumi Jinguji, Yoshihiko Fukukura, Masayuki Nakajo, Yoriko Kajiya, Atsushi Tani   FDG and FLT PET/CT studies for discriminating between benign and malignant adrenal tumors   International conference

    SNM 2013  SNM 2013

     More details

    Event date: 2014.6

    Language:English  

    Venue:セントルイス  

    国際学会

  • Masatoyo Nakajo, Megumi Jinguji,Yoshihiko Fukukura, Masayuki Nakajo, Yoriko Kajiya, Atsushi Tani   FLT-PET/CT findings of adrenal tumors  

    第73回日本医学放射線学会総会  第73回日本医学放射線学会総会

     More details

    Event date: 2014.4

    Language:Japanese  

    Venue:神奈川  

    国内学会

  • Masatoyo Nakajo, Masayuki Nakajo, Yoshihiko Fukukura, Megumi Jingugi, Yoshiaki Nakabeppu   The value of intratumoral heterogeneity of FDG uptake to differentiate between benign and malignant primary musculoskeletal tumors on PET/CT   International conference

    RSNA 99th Scientific Assembly and Annual Meeting  RSNA 99th Scientific Assembly and Annual Meeting

     More details

    Event date: 2013.12

    Language:English  

    Venue:シカゴ  

    国際学会

  • 中條 正豊, 神宮司 メグミ, 福倉 良彦, 中別府 良昭, 加治屋より子, 谷 淳至, 中條 正典, 中條 政敬   後腹膜腫瘍2症例のFDG 及びFLT PET/CT所見  

    第53回日本核医学学術総会  第53回日本核医学学術総会

     More details

    Event date: 2013.11

    Language:Japanese  

    Venue:福岡  

    国内学会

  • Masatoyo Nakajo, Yoriko Kajiya, Masayuki Nakajo   Our clinical experience with FLT PET/CT   International conference

    CJK 2013  CJK 2013

     More details

    Event date: 2013.11

    Language:English  

    Venue:韓国  

    国際学会

  • Masatoyo Nakajo, Masayuki Nakajo, Yoriko Kajiya, Yoshihiko Fukukura, Megumi Jinguji, Nobuaki Nishimata, Shunji Shimaoka, Kuniaki Aridome, Sadao Tanaka, Yuko Gotoh   Effect of pathological factors on visibility of lymph node metastasis from colorectal cancer with FLT PET/CT   International conference

    SNM 2013  SNM 2013

     More details

    Event date: 2013.6

    Language:English  

    Venue:カナダ  

    国際学会

  • 中條正豊, 福倉良彦, 神宮司メグミ, 進藤俊和, 中別府良昭, 中條政敬   副腎腫瘍のFDG-PET及び拡散強調画像の検討  

    第72回日本医学放射線学会総会  第72回日本医学放射線学会総会

     More details

    Event date: 2013.4

    Language:Japanese  

    Venue:神奈川  

    国内学会

  • Masatoyo Nakajo, Megumi Jingugi, Atushi Tani, Hiroaki Tanabe, Yoriko Kajiya, Yoshihiko Fukukura, Yoshiaki Nakabeppu, Masayuki Nakajo   Comparison of FDG-PET/CT and FLT-PET/CT for postoperative thyroid cancer   International conference

    RSNA 98th Scientific Assembly and Annual Meeting  RSNA 98th Scientific Assembly and Annual Meeting

     More details

    Event date: 2012.11

    Language:English  

    Venue:シカゴ  

    国際学会

  • 中條正豊, 加治屋より子, 神宮司メグミ, 田邊博昭, 中別府良昭, 福倉良彦,中條政敬   大腸癌のFLT PET陽性と陰性のリンパ節転移の検討  

    第52回日本核医学会学術総会  第52回日本核医学会学術総会

     More details

    Event date: 2012.10

    Language:Japanese  

    Venue:札幌  

    国内学会

  • Masatoyo Nakajo, Masayuki Nakajo, Yoriko Kajiya, Yoshihiko Fukukura, Megumi Jingugi, Nobuaki Nishimata,Tohru Nihara, Shunji Shimaoka, Kuniaki Aridome, Sadao Tanaka, Michiyo Higashi   FDG-PET/CT and FLT-PET/CT Imaging of Colorectal Cancer   International conference

    SNM 2012  SNM 2012

     More details

    Event date: 2012.6

    Language:English  

    Venue:マイアミ  

    国際学会

  • 中條正豊, 田邊博明, 加治屋より子, 神宮司メグミ, 中別府良昭, 中條政敬   甲状腺癌術後の病期診断におけるFDG PET及びFLT-PETの検討  

    第71回日本医学放射線学会総会  第71回日本医学放射線学会総会

     More details

    Event date: 2012.4

    Language:Japanese  

    Venue:神奈川  

    国内学会

  • 中條正豊, 田邊博昭 ,中別府良昭 ,中條政敬, 加治屋より子, 神宮司メグミ, 上野いづみ, 田野畑佐也佳   大腸癌におけるFDG とFLT によるPET/CTの比較検討  

    第51回日本核医学会学術総会  第51回日本核医学会学術総会

     More details

    Event date: 2011.11

    Language:Japanese  

    Venue:茨城  

    国内学会

  • Masatoyo Nakajo, Masayuki Nakajo, Yoriko Kajiya, Atsushi Tani, Takuro Kamiyama, Ryuji Yonekura, Yoshihiko Fukukura, Tsutomu Matsuzaki, Kengo Nishimoto, Mitsuharu Nomoto, Chihaya Koriyama   FDG-PET/CT and Diffusion-Weighted Imaging of Head and Neck Squamous Cell Carcinoma: Comparison of Prognostic Significance between Primary Tumor Standardized Uptake Value and Apparent Diffusion Coefficient   International conference

    EANM 2011  EANM 2011

     More details

    Event date: 2011.10

    Language:English  

    Venue:イギリス  

    国際学会

  • 中條正豊, 中條政敬, 加治屋より子, 谷淳, 神山拓郎, 米倉隆治, 松崎勉、西元謙吾, 野元三治   頭頸部癌のFDG-PET及び拡散強調画像の検討: SUV及びADCと予後因子の関係  

    第70回日本医学放射線学会総会  第70回日本医学放射線学会総会

     More details

    Event date: 2011.4

    Language:Japanese  

    Venue:神奈川  

    国内学会

  • Tani Atsushi, Jinguji Megumi, Nakajo Masatoyo, Yoshiura Takashi   骨軟骨腫のSPECT/CT トレーサー集積分布および強度の視覚的評価(Bone SPECT/CT in Osteochondromas: Visual Analysis of Tracer Distribution and Intensity)  

    日本医学放射線学会学術集会抄録集  2019.2  (公社)日本医学放射線学会

  • 長野 広明, 神宮司 メグミ, 中條 正典, 中條 正豊, 吉浦 敬, 中條 政敬, 東 美智代, 永野 聡   骨シンチグラフィおよびFDG-PET/CTで高集積を認めた両脛骨の骨線維性異形成(Osteofibrous dysplasia)の1例  

    Japanese Journal of Radiology  2018.2  (公社)日本医学放射線学会

  • 甲斐田 勇人, 北島 一宏, 中條 正豊, 石橋 愛, 南本 亮吾, 平田 健司, 中谷 航也, Ao Hung, 服部 聡, 安田 卓司, 石井 一成   食道癌の術前化学療法に対するFDG-PET/CTの有用性 多施設共同研究  

    核医学  2020.10  (一社)日本核医学会

  • 谷 淳至, 神宮司 メグミ, 中條 正豊, 吉浦 敬   褐色脂肪組織へのFDG集積に関する患者因子の検討  

    核医学  2018.11  (一社)日本核医学会

  • Nakajo Masatoyo, Jinguji Megumi, Tani Atsushi, Yoshiura Takashi   胸腺上皮性腫瘍の悪性度を予測する18F-FDG PET/CTの有用性(Value of 18F-FDG PET/CT in Predicting the Malignant Grade of Thymic Epithelial Tumors)  

    日本医学放射線学会学術集会抄録集  2017.2  (公社)日本医学放射線学会

  • 中條 正豊, 神宮司 メグミ, 谷 淳至, 吉浦 敬   肝機能評価における99mTc GSA SPET/CTのSUV値解析の有用性に関する研究  

    核医学  2020.10  (一社)日本核医学会

  • Nakajo Masatoyo   結腸直腸癌における18F-FDG-PET/CTおよび18F-FLT-PET/CTの臨床応用(Clinical applications of 18F-FDG-PET/CT and 18F-FLT-PET/CT in colorectal cancer)  

    核医学  2018.11  (一社)日本核医学会

  • Nakajo Masatoyo   結腸直腸癌における18F-FDG PET/CTおよび18F-FLT-PET/CTの臨床応用(Clinical applications of 18F-FDG-PET/CT and 18F-FLT-PET/CT in colorectal cancer)  

    核医学技術  2018.10  (NPO)日本核医学技術学会

  • 谷 淳至, 神宮司 メグミ, 吉浦 敬, 中條 正豊   甲状腺癌術後の胸腺過形成と考えられた1例 FDG-PET/CTとI-131 SPECT/CTとの比較  

    Japanese Journal of Radiology  2019.2  (公社)日本医学放射線学会

  • 谷 淳至, 神宮司 メグミ, 吉浦 敬, 中條 正豊   甲状腺癌に対する複数回の放射性ヨード内用療法が耳下腺への放射性ヨード集積に与える影響についての検討  

    核医学  2017.9  (一社)日本核医学会

  • Nakajo Masatoyo, Jinguji Megumi, Tani Atsushi, Yoshiura Takashi   甲状腺癌におけるFDG-PET/CTのvolumetric解析による術後高リスク再発群予測の有用性について(Value of Volumetric Analysis of 18F-FDG-PET/CT for Predicting the Risk of Recurrence in Differentiated Thyroid Cancer after Total Thyroidectomy)  

    日本医学放射線学会学術集会抄録集  2018.2  (公社)日本医学放射線学会

  • Tani Atsushi, Kajiya Yoriko, Nakajo Masatoyo, Jinguji Megumi, Yoshiura Takashi   消化管膵神経内分泌腫瘍 FDG-PET/CTと拡散強調MRIの比較(Gastroenteropancreatic Neuroendocrine Tumor: Comparison of FDG-PET/CT and Diffusion-weighted MRI)  

    日本医学放射線学会学術集会抄録集  2017.2  (公社)日本医学放射線学会

  • Nakajo Masatoyo   核医学による腫瘍学的評価と治療戦略のための臨床適応 腫瘍学における18F-FLT PETまたはPET/CTの臨床での現状(Oncological Evaluation by Nuclear Medicine and Clinical Applications for Therapeutic Strategy Current Clinical Status of 18F-FLT PET or PET/CT in Oncology)  

    日本医学放射線学会学術集会抄録集  2017.2  (公社)日本医学放射線学会

  • 河路 広大, 神宮司 メグミ, 中條 正豊, 谷 淳至, 吉浦 敬   急性下顎骨骨髄炎における骨シンチグラフィの検討  

    核医学  2019  (一社)日本核医学会

  • 神宮司 メグミ, 中條 正豊, 谷 淳至, 中條 政敬, 吉浦 敬   巨大な甲状腺腫を有するバセドウ病に対するI-131治療経験  

    核医学  2017.9  (一社)日本核医学会

  • 谷 淳至, 神宮司 メグミ, 中條 正豊, 吉浦 敬   少量(1110MBq)のI-131を用いた甲状腺癌術後アブレーション治療の効果判定  

    核医学  2020.10  (一社)日本核医学会

  • 谷 淳至, 神宮司 メグミ, 中條 正豊, 吉浦 敬   多発する弾性線維腫へのFDG集積と思われる所見を認めた1例  

    Japanese Journal of Radiology  2020.2  (公社)日本医学放射線学会

  • 中條 正豊, 神宮司 メグミ, 谷 淳至, 吉浦 敬   副腎腫瘍の良悪性鑑別におけるFDG-PET/CTでのテクスチャー解析の有用性の検討  

    核医学  2017.9  (一社)日本核医学会

  • 中條 正豊   初回治療後の病期診断の現況とブレークスルー(領域横断的セッション) 食道癌術前化学放射線療法後のPERCISTの治療効果判定と予後予測における有用性  

    日本食道学会学術集会プログラム・抄録集  2020.12  (NPO)日本食道学会

  • 大崎 洋充, 鳥井原 彰, 石橋 愛, 伊藤 公輝, 坂本 史, 中條 正豊, 中原 理紀, 渡部 直史, 北島 一宏   免疫チェックポイント阻害剤の治療効果判定・治療効果予測における後方視的SUV調和の多施設共同研究  

    核医学  2020.10  (一社)日本核医学会

  • 中條 正豊   人工知能診断の最前線:各分野のスペシャリストに聞く なぜ今、AI診断があついのか  

    核医学  2018.11  (一社)日本核医学会

  • 谷 淳至, 神宮司 メグミ, 中條 正豊, 吉浦 敬   下顎骨骨髄炎・骨壊死の定量的な骨SPECT/CT評価の試み  

    核医学  2019.10  (一社)日本核医学会

  • Nakajo Masatoyo, Jinguji Megumi, Tani Atsushi, Yoshiura Takashi   テクスチャー解析を用いた18F-FDG PET/CTによる肺腫瘤の良悪性鑑別の有用性の検討(Value of Texture Features of 18F-FDG-PET/CT Imaging for Differentiating between Benign and Malignant Pulmonary Lesions)  

    日本医学放射線学会学術集会抄録集  2019.2  (公社)日本医学放射線学会

  • 谷 淳至, 中條 正豊, 神宮司 メグミ, 吉浦 敬, 加治屋 より子   FLTの大動脈壁への集積と思われる所見が認められた一例  

    核医学  2017.2  (一社)日本核医学会

  • 神宮司 メグミ, 中條 正豊, 谷 淳至, 吉浦 敬   FDG-PET/CTの腹壁異常集積の検討  

    核医学  2019.10  (一社)日本核医学会

  • 長野 広明, 神宮司 メグミ, 谷 淳至, 中條 正豊, 吉浦 敬   111In-pentetreotideシンチグラフィの撮像タイミングと腫瘍/正常臓器集積比に関する検討  

    核医学  2017.2  (一社)日本核医学会

  • 惠島 史貴, 長野 広明, 神宮司 メグミ, 谷 淳至, 中條 正豊, 吉浦 敬   111In-pentetreotideシンチグラフィにおける膵鉤部生理的集積についての検討  

    核医学  2017.2  (一社)日本核医学会

  • Nakajo Masatoyo   非小細胞肺癌の免疫療法における治療効果判定のための18F-FDG PET/CTの現状(Current Clinical Status of 18F-FDG PET/CT for Evaluation of Treatment Response to Immunotherapy in Non-small Cell Lung Cancer)  

    日本医学放射線学会学術集会抄録集  2021.3  (公社)日本医学放射線学会

     More details

    Language:English  

  • Nakajo Masatoyo, Jinguji Megumi, Tani Atsushi, Yoshiura Takashi   子宮内膜癌患者における術前18F-FDG-PET/CTのボリューム解析およびテクスチャー解析を用いたリスク分類(Risk Stratification using Volumetric and Texture Analyses of Preoperative 18F-FDG-PET/CT in Patients with Endometrial Cancer)  

    日本医学放射線学会学術集会抄録集  2021.3  (公社)日本医学放射線学会

     More details

    Language:English  

  • 谷 淳至, 中條 正豊, 神宮司 メグミ, 吉浦 敬   転移性肺腫瘍へのFDG集積におけるデバイスレス呼吸同期撮影法の影響 領域毎の評価  

    核医学  2022.8  (一社)日本核医学会

     More details

    Language:Japanese  

  • Nakajo Masatoyo, Jinguji Megumi, Tani Atsushi, Horizoe Yoshihisa, Yoshiura Takashi   褐色細胞腫患者の心機能評価における123I-MIBG心筋集積の視覚的およびSUV定量解析の有用性の検討(Value of Myocardial 123I-MIBG Uptake Assessed by Visual and Semiquantitative Analyses for Characterizing the Cardiac Function in Patients with Pheochromocytoma)  

    日本医学放射線学会学術集会抄録集  2022.3  (公社)日本医学放射線学会

     More details

    Language:English  

  • 谷 淳至, 神宮司 メグミ, 中條 正豊, 吉浦 敬   肺動静脈奇形に対する血管内治療前後のTc-99m MAAを用いた評価法に関する検討  

    核医学  2021.10  (一社)日本核医学会

     More details

    Language:Japanese  

  • 中條 正豊   核医学~近未来核医学の向かう道-診断・治療の精度をあげる最新手法~ Dynamic PET/CTを用いた18F-FDG-PET Ki parametric imageの臨床応用について  

    日本医学放射線学会秋季臨床大会抄録集  2022.8  (公社)日本医学放射線学会

     More details

    Language:Japanese  

  • 田中 嵩人, 中條 正豊, 本村 江利子, 藤阪 智史, 神宮司 メグミ, 谷 淳至, 西郷 康正   心サルコイドーシスの18F-FDG-PET/CT速度定数画像の短時間撮像による画像再構成法の検討  

    核医学技術  2021.10  (NPO)日本核医学技術学会

     More details

    Language:Japanese  

  • 中條 正豊, 神宮司 メグミ, 谷 淳至, 吉浦 敬   子宮頸癌の予後予測におけるFDG-PET特徴量を利用した機械学習解析について  

    核医学  2021.10  (一社)日本核医学会

     More details

    Language:English  

  • 中條 正豊   18F-FDG-PET/CTを中心とした腫瘍核医学ならびに神経内分泌腫瘍におけるtheranosticsについて  

    核医学  2022.8  (一社)日本核医学会

     More details

    Language:Japanese  

  • Nakajo Masatoyo, Jinguji Megumi, Hirahara Mitsuho, Tani Atsushi, Yoshiura Takashi   Value of Volumetric Analysis of 18F-FDG-PET/CT for Predicting the Prognosis in Patients with Gallbladder Cancer(タイトル和訳中)  

    日本医学放射線学会学術集会抄録集  2023.3  (公社)日本医学放射線学会

     More details

    Language:English  

  • Ejima Fumitaka, Fukukura Yoshihiko, Ayukawa Takuro, Nakajo Masanori, Nagano Hiroaki, Takumi Koji, Nakajo Masatoyo, Kamimura Kiyohisa, Yoshiura Takashi   Multiparametric MRI for Preoperative Prediction of Lymph Node Metastases in Patients with Uterine Endometrial Cancer(タイトル和訳中)  

    日本医学放射線学会学術集会抄録集  2023.3  (公社)日本医学放射線学会

     More details

    Language:English  

▼display all

Awards

  • 日本核医学会賞(2022年度)

    2022.9   日本核医学会  

    中條 正豊

     More details

    Award type:Award from Japanese society, conference, symposium, etc.  Country:Japan

  • 日本医学放射線学会第29回優秀論文賞

    2017.4   日本医学放射線学会  

    中條 正豊

     More details

    Award type:International academic award (Japan or overseas)  Country:Japan

  • 第8回日本核医学会研究奨励賞

    2011.11   日本核医学会  

    中條 正豊

     More details

    Award type:International academic award (Japan or overseas)  Country:Japan

Research Projects

  • FDG-PET代謝速度定数画像による免疫チェックポイント阻害剤効果判定法の確立

    2022.4 - 2025.3

    科学研究費補助金 基盤研究(C) 

      More details

    Authorship:Principal investigator 

  • The clinical usefulness of FDG-PET image for predicting histological type, staging and deciding the treatment strategy for thymic epithelial tumors

    2019.10 - 2021.3

    Private Enterprise 

    Nakajo Masatoyo

  • Comparative evaluation of 18F-FDG static (SUV) PET imaging and Patlak (Ki) 18F-FDG PET

    2019.9 - 2022.8

    Private Enterprise 

  • 18F-FDGの速度定数画像に基づく心サルコイド-シスの活動性評価法の開発

    2019.4 - 2022.3

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator